Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment

Description

BACKGROUND

Focal ablation and other cell membrane disruption therapies and molecule delivery mechanisms are used in many clinical and research applications. As such, monitoring techniques for lesion/treatment area are desirable. As such, there exists a need for improved monitoring techniques for use, inter alia, focal ablation and other cell membrane disruption therapies.

SUMMARY

Provided herein are embodiments of an electrical conductivity sensor having an impedance sensor, where the impedance sensor can be configured to measure a low-frequency and a high-frequency impedance and a substrate, where the impedance sensor is coupled to the substrate. The substrate can be flexible. In embodiments, the impedance sensor can contain two or more electrical conductors. The electrical conductors can be in a bipolar configuration. The electrical conductors can be in a tetrapolar configuration. In embodiments, the electrical conductivity sensor can have two impedance sensors that can be coupled to the substrate such that they are orthogonal to each other.

In embodiments, the electrical conductivity sensor can have more than one impedance sensor. In some embodiments, the impedance sensors can be configured in an array. In embodiments having more than one impedance sensor, the electrical conductivity sensor can further contain a common ground, where each impedance sensor is coupled to the common ground. In embodiments having more than one impedance sensor, the electrical conductivity sensor can further contain a common counter electrode, wherein the common counter electrode can be coupled to the substrate.

In embodiments, the impedance sensor(s) can have interdigitated electrodes. In embodiments, the impedance sensor(s) can further contain a receptor molecule configured to specifically bind a target molecule, wherein the receptor molecule is coupled to the sensor(s).

In embodiments, the electrical conductivity sensor can contain one or more sensors configured to detect a tissue characteristic selected from the group of: pH, temperature, a chemical concentration, a nucleic acid concentration, a gas amount, or combinations thereof.

Also provided herein are embodiments of an electrical conductivity probe having an elongated member and an electrical conductivity sensor as described herein where the electrical conductivity sensor can be coupled to the elongated member. In embodiments, the electrical conductivity sensor can be removably coupled to the elongated member.

Also provided herein are embodiments of a system having an electrical conductivity probe as described herein, a treatment probe configured to deliver an energy to a tissue, where the energy can be sufficient to disrupt a cell membrane, an impedance analyzer, where the impedance analyzer can be coupled to the electrical conductivity probe, a low voltage power supply, where the low voltage power supply can be coupled to the electrical conductivity probe and can be configured to deliver a low voltage energy to the electrical conductivity probe, a waveform generator, where the waveform generator can be coupled to the low voltage power supply, a gate driver, where the gate driver can be coupled to the waveform generator and the low voltage power supply, a high voltage switch, where the high voltage switch can be coupled to the treatment probe and the impedance analyzer; and a high voltage power supply, where the high voltage power supply can be coupled to the high voltage switch.

In embodiments, the system can further contain a computer. The computer can be coupled to the impedance analyzer and the computer can contain processing logic that can be configured to determine the position of lesion or treated area front within a tissue undergoing focal ablation/cell membrane disruption therapy. The processing logic can be further configured to generate a signal to a user when the position of lesion or treated area front has reached a predetermined position within the tissue. The processing logic can be configured to automatically manipulate the system to adjust or stop treatment of a tissue by the treatment probe when the position of lesion or treated area front has reached a predetermined position within the tissue.

In embodiments, the treatment probe and the electrical conductivity probe can be the same probe. In embodiments, the treatment probe and the electrical conductivity probe are separate probes. The treatment probe can be coupled to a grounding pad located elsewhere relative to the treatment probe in or on the body of a subject being treated.

Also provided herein are embodiments of a method of monitoring the lesion or treated area front or size during focal ablation or cell membrane disruption therapy, the method have the steps of inserting an electrical conductivity probe as described herein into a tissue, inserting a treatment probe into the tissue, applying a treatment to the tissue, wherein the treatment comprises applying an energy to the tissue via the treatment probe, and measuring a characteristic of the tissue continuously during treatment, determining if there is a change in the tissue characteristic. The characteristic can be impedance. In some embodiments, the step of measuring can include measuring both low-frequency impedance and high-frequency impedance and further comprising the step of stopping or adjusting treatment when low-frequency impedance is equal to high-frequency impedance. In embodiments, the characteristic can be pH, temperature, a gas concentration, a chemical concentration, a nucleic acid concentration, or a combination thereof. In some embodiments, the method can contain the step of stopping or adjusting a treatment when a change in the tissue characteristic is detected. In embodiments, the method can contain the step of alerting a user when a change in the tissue characteristic is detected.

In some embodiments, where the electrical conductivity probe includes an impedance sensor array, the method can include the step of determining the location of the lesion or treated area front or size by comparing impedance data between two or more impedance sensors of the impedance sensor array. In embodiments, the method can include the step of comparing the lesion or treated area front or size to a threshold value and stopping treatment when lesion or treated area front or size is greater than or equal to the threshold value. In embodiments, the method can include the step of comparing the lesion or treated area front or size to a threshold value and alerting a user when lesion or treated area front or size is greater than or equal to the threshold value.

The method can include the steps of comparing measured changes in impedance to a solution for the electric field distribution during focal ablation or cell membrane disruption and determining the 2D/3D lesion or treated area geometry of the lesion or treated area volume. In embodiments, the method can include the step of overlaying the 2D/3D lesion or treated area geometry on one or more medical images of a subject to generate an image overlay. The method can include the step of visualizing lesion or treatment area front migration or lesion or treatment area growth from the image overlay.

BRIEF DESCRIPTION OF THE DRAWINGS

Further aspects of the present disclosure will be readily appreciated upon review of the detailed description of its various embodiments, described below, when taken in conjunction with the accompanying drawings.

FIG. 1 shows embodiments of an electrical conductivity sensor.

FIG. 2 shows embodiments of an electrical conductivity sensor.

FIG. 3 shows embodiments of an electrical conductivity sensor.

FIG. 4 shows embodiments of an electrical conductivity sensor.

FIG. 5 shows embodiments of an electrical conductivity sensor.

FIG. 6 shows embodiments of an electrical conductivity sensor.

FIG. 7 shows embodiments of an electrical conductivity sensor.

FIG. 8 shows embodiments of an electrical conductivity sensor.

FIG. 9 shows embodiments of an electrical conductivity probe.

FIG. 10 shows embodiments of an electrical conductivity probe.

FIG. 11 shows embodiments of an electrical conductivity probe.

FIG. 12 shows embodiments of an electrical conductivity probe.

FIG. 13 shows embodiments of an electrical conductivity probe.

FIG. 14 shows embodiments of a system configured to monitor lesion/treated area formation in real-time.

FIG. 15 shows embodiments of a system configured to monitor lesion/treated area formation in real-time.

FIGS. 16A-16B show embodiments of operation of an electrical conductivity probe during treatment to monitor lesion/treated area formation in real-time.

FIGS. 17A-17C show embodiments of operation of an electrical conductivity probe during treatment to monitor lesion/treated area formation in real-time.

FIG. 18 shows an image of an embodiment of an electrical conductivity sensor.

FIG. 19 shows an image of an embodiment of an electrical conductivity sensor.

FIG. 20 shows an image of an embodiment of an electrical conductivity sensor.

FIG. 21 shows an image of an embodiment of an electrical conductivity probe.

FIGS. 22A-22J shows steps in a process for manufacturing an electrical conductivity sensor.

FIGS. 23A-23B show a three dimensional finite element model to simulate IRE treatment of liver tissue with two needle electrodes.

FIGS. 24A-24B show the simulated electrical conductivity in the tissue resulted from IRE (FIG. 24A) and simulated extrapolation of point specific measurements in three dimensions to determine the spatial-temporal conductivity map and electric field distribution (FIG. 24B).

FIGS. 25A and 25B show images of a probe FIG. 25A and placement within a sample of porcine liver. The dashed circle in FIG. 2B indicates the treated area. The black dots indicate location of the sensors of the probe within the tissue.

FIG. 26 shows a graph demonstrating tissue resistance (ohms) after delivery of a series of high-frequency irreversible electroporation (HFIRE) pulses to the porcine liver of FIG. 25B as measured by the probe of FIG. 25A.

FIG. 27 shows a graph demonstrating % change in tissue resistance between varying sensors after delivery of a series of high-frequency irreversible electroporation (HFIRE) pulses to the porcine liver of FIG. 25B as measured by the probe of FIG. 25A.

FIGS. 28A-28D show images of a 3D isometric view of the probe onto ortho-planes from stacked CT images of patient anatomy.

FIGS. 29A-29C show graphs demonstrating finite element modeling (FEM) of electric field magnitude along the length of the probe in a potato model, where N=10 (FIG. 29A), N=30 (FIG. 29B), and N=100 (FIG. 29C).

FIGS. 30A-30C show graphs demonstrating experimental results of conductivity change as measured by different sensor pairs along the length of the probe in a potato model, where N=10 (FIG. 30A), N=30 (FIG. 30B), and N=100 (FIG. 30C).

FIGS. 31A-31C show photos demonstrating experimental ablations after delivering a series of IRE pulses to a potato model where N=10 (FIG. 31A), N=30 (FIG. 31B), and N=100 (FIG. 31C).

FIG. 32 shows embodiments of installation of a sensor array on a probe and the electrical connections to the sensor.

FIGS. 33A-33B shows the electrical impedance spectrum of the porcine liver (FIG. 33A) along with the equivalent circuit model of the tissue (FIG. 33B).

FIG. 34 shows an embodiment of a system where a monopolar electrode and a grounding pad are used to deliver the high voltage pulses.

FIG. 35 shows another embodiment of a system where a monopolar electrode and a grounding pad are used to deliver the high voltage pulses.

DETAILED DESCRIPTION

Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.

All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be independently confirmed.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.

Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of mechanical engineering, electrical engineering, physiology, medical science, veterinary science, bioengineering, biomechanical engineering, physics, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.

Definitions

As used herein, “about,” “approximately,” and the like, when used in connection with a numerical variable, generally refers to the value of the variable and to all values of the variable that are within the experimental error (e.g., within the 95% confidence interval for the mean) or within .+−.10% of the indicated value, whichever is greater.

As used herein, “control” is an alternative subject or sample used in an experiment for comparison purposes and included to minimize or distinguish the effect of variables other than an independent variable. A “control” can be a positive control, a negative control, or an assay or reaction control (an internal control to an assay or reaction included to confirm that the assay was functional). In some instances, the positive or negative control can also be the assay or reaction control.

As used interchangeably herein, “subject,” “individual,” or “patient,” refers to a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. The term “pet” includes a dog, cat, guinea pig, mouse, rat, rabbit, ferret, and the like. The term farm animal includes a horse, sheep, goat, chicken, pig, cow, donkey, llama, alpaca, turkey, and the like.

As used herein, “biocompatible” or “biocompatibility” refers to the ability of a material to be used by a patient without eliciting an adverse or otherwise inappropriate host response in the patient to the material or an active derivative thereof, such as a metabolite, as compared to the host response in a normal or control patient.

As used herein, “therapeutic” can refer to curing and/or treating a symptom of a disease or condition.

The term “treating”, as used herein, can include inhibiting and/or resolving the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and/or condition. Treating the disease, disorder, or condition can include ameliorating at least one symptom of the particular disease, disorder, or condition, even if the underlying pathophysiology is not affected, such as treating the pain of a subject by administration of an analgesic agent even though such agent does not treat the cause of the pain.

The term “preventing”, as used herein includes preventing a disease, disorder or condition from occurring in a subject, which can be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it. As used herein, “preventative” can refer to hindering or stopping a disease or condition before it occurs or while the disease or condition is still in the sub-clinical phase.

The term “target molecule” can refer to any specific desired molecule including, but not limited to, a nucleic acid, oligonucleotide, polynucleotide, peptide, polypeptide, chemical compound, or other molecule that can specifically bind to a receptor molecule. Typically, the target molecule refers to a molecule that can be located in a sample or tissue whose presence and/or amount can be determined by detecting its binding to known receptor molecule.

The term “receptor molecule” can refer to a molecule that can specifically bind to a target molecule. A receptor molecule can be a nucleic acid, oligonucleotide, polynucleotide, peptide, polypeptide, chemical compound, or other molecule. Receptor molecules can be, for example, antibodies or fragments thereof or aptamers. The receptor molecule can be bound, fixed, or otherwise attached to a surface, sometimes in known location (e.g. as in an array), and can be exposed to a sample such that if a target molecule is present, the target molecule can interact and specifically bind with the receptor molecule. The specific binding can, in some cases, trigger a signal that can provide quantitative and/or qualitative information regarding the target molecule.

As used herein, “specific binding,” “specifically bound,” and the like, refer to binding that occurs between such paired species as nucleotide/nucleotide, enzyme/substrate, receptor/agonist, antibody/antigen, and lectin/carbohydrate that can be mediated by covalent or non-covalent interactions or a combination of covalent and non-covalent interactions. When the interaction of the two species produces a non-covalently bound complex, the binding which occurs is typically electrostatic, hydrogen-bonding, or the result of lipophilic interactions. Accordingly, “specific binding” occurs between a paired species where there is interaction between the two which produces a bound complex having the characteristics of an antibody/antigen or enzyme/substrate interaction. In particular, the specific binding is characterized by the binding of one member of a pair to a particular species and to no other species within the family of compounds to which the corresponding member of the binding member belongs. Thus, for example, an antibody preferably binds to a single epitope and to no other epitope within the family of proteins.

As used herein, “aptamer” refers to single-stranded DNA or RNA molecules that can bind to pre-selected targets including proteins with high affinity and specificity. Their specificity and characteristics are not directly determined by their primary sequence, but instead by their tertiary structure.

Discussion

Focal cell ablation and focal cell membrane disruption techniques can be used to selectively destroy undesired tissue, deliver drugs to cells and tissues, and deliver nucleic acids to cells. Focal ablation and membrane disruption techniques can be thermally or non-thermally based. Thermally based techniques use heat to ablate cells or disrupt cell membranes and include, but are not limited to, radiofrequency (RF) ablation, laser ablation, cryo-ablation, and ultrasound. Other thermal focal ablation/membrane disruption techniques will be appreciated by those of ordinary skill in the art. Non-thermal techniques can rely on the generation or application of an electric field to cells to disrupt (reversibly or irreversibly) the cell membrane, which increases the permeability or kills the cells. Non-thermal focal ablation/membrane disruption techniques include, but are not limited to electroporation. Other Non-thermal focal ablation/membrane disruption techniques will be appreciated by those of ordinary skill in the art. During these techniques, it is difficult to determine the extent of treatment within a tissue being treated. As such, current procedures relying on focal ablation and membrane disruption techniques are imprecise, which can result in undesirable side effects, destruction of, or gene/transcript/protein modification in normal or otherwise healthy cells.

Membrane permeability changes induced by focal ablation/cell membrane disruption techniques at the cell level can translate into changes in impedance at the tissue level. Known devices and methods of monitoring tissue impedance, such as during electroporation, have several drawbacks. Primarily, they rely on bulk tissue properties as opposed to measurements at well-defined points within the tissue being treated. Bulk changes can be useful in describing how the dielectric properties of the tissue change as a whole during treatment. However, there is no specificity in terms of the location where treatment is occurring. In known devices and methods, this information is usually inferred from correlations with predications of the electric field distribution in the tissue. In other words, the treatment zone is defined as the area above a pre-determined threshold that is based on the inferred correlations and predications. The bulk measurements can be made either through the treatment electrodes or with a separate set of electrodes, where the electrodes located in proximity to each other.

As an alternative, electrical impedance tomography (EIT) can be used to map the tissue dielectric potential throughout the entire treatment region based on solutions to a nonlinear inverse that accounts for surface electrical measurements. However, this imaging technique is complicated by the required placement of an electrode array around the periphery of the target tissue. Placement of the electrode array can be difficult to implement clinically because some tumors and other target tissues do not accommodate the placement of such an array due to geometrical/anatomical constraints or the presence of highly insulating anatomical structures such as the skull or skin. Further, EIT suffers from the limitations associated with the resolution of reconstructed images, which relies heavily on the accurate placement and number of external electrodes. Moreover, none of the existing technologies and methods can achieve active, real-time monitoring of the lesion or treated area front during focal ablation and cell membrane disruption procedures.

With these shortcomings in mind, described herein are devices and systems that can be configured to monitor a lesion or treated area front in real-time during focal ablation/membrane disruption therapy. The devices and systems can be configured with a sensor array to detect a lesion or treated area front. The devices and systems provided herein can be used to actively monitor focal ablation/cell membrane disruption therapy in real-time and thus can allow a practitioner to control, adjust, and/or discontinue treatment in response to front migration to minimize treatment side effects.

Also described herein are methods of monitoring a lesion or treated area front in real-time in tissue during focal ablation/membrane disruption. The methods can include alerting a user when the front has reached a desired location. The methods can utilize both low- and high-frequency electrical impedance measurements to determine if the tissue area surrounding a sensor has been ablated or treated. The devices, systems and methods described herein can provide for focal ablation/membrane disruption techniques and therapies with improved specificity than current techniques and devices. Other devices, systems, methods, features, and advantages of the present disclosure will be or become apparent to one having ordinary skill in the art upon examination of the following drawings, detailed description, and examples. It is intended that all such additional compositions, compounds, methods, features, and advantages be included within this description, and be within the scope of the present disclosure.

Systems and Devices for Real-Time Impedance Monitoring

During focal ablation or cell membrane disruption procedures, as the procedure continues the treated area or lesion expands out from the treatment source. A feature common to these types of therapies is a change in the membrane permeability of the cell membranes that have been stimulated during focal ablation or cell membrane disruption. Focal ablation and other membrane disruption techniques can result in a change in impedance in due to a change in the permeability of the cells that have been sufficiently stimulated during focal ablation or cell membrane disruption.

As the lesion or treated area forms as treatment continues, an increasing number of cells in the tissue surrounding the treatment source undergo a membrane disruption and thus a change in the impedance of the cells in that area. As the lesion/treated area grows, a front can be formed that forms a boundary between treated and untreated cells. The treated cells and the untreated cells can have different impedances or other characteristics (e.g. pH and temperature). By measuring the impedance or other characteristic between two or more points in the tissue during treatment, it can be possible to determine if the front lies between those two points. The position of the lesion/treated area front within a tissue being treated can also be made by measuring impedance or other tissue characteristic at a single point and comparing that to a base line or prior measurement from that point.

Provided herein are systems and devices that can be configured to detect and determine the location of a lesion/treated area front in real-time during a focal ablation or cell membrane disruption therapy. The systems and devices can also be configured to generate 3D images and models from lesion/treated area front measurements that can provide the volume of a lesion/treated area. The systems and devices can be configured to provide automatic control of a treatment in response to detection of the migration of the lesion/treated area front. The systems and devices can be configured to provide a signal to a user in response to detection of the migration of the lesion/treated area front.

Biological tissue is a combination of extracellular space, cellular membranes, and subcellular structures, each of which contains organic molecules and ions in different structural arrangements. This can result in a broad spectrum of dielectric properties across multiple frequencies. In other words, the dielectric properties of tissue are frequency dependent. From around 0.1 Hz to 10 MHz, there exist two main dispersive regions: (1) the α, or low frequency, dispersion region and (2) the β, or high frequency, region. The α region ranges from about 0.1 Hz to about 10 Hz and the β region ranges from about 0.1 MHz to about 10 MHz. The α region is due to counter ion polarization effects along cell membranes. The β region is due to the Maxwell-Wagner effects. This describes the charging and relaxation effects along cell membranes, which act as barriers to the movement of ions.

Above the β dispersion, cell membranes have negligible impedance and current can pass freely through the cell membrane. This is similar to what happens during, for example, electroporation, when pore formation reduces the membrane impedance and permits current to enter the cell. As a result, low frequency (α region) electrical measurements at a location in a tissue before and after focal ablation or cell membrane disruption can be compared to determine if the focal ablation or cell membrane disruption has reached its endpoint at that position in the tissue. At the endpoint, the low frequency (α region) impedance is about equal to the high-frequency (β region) impedance, which is due to the focal ablation or cell membrane disruption in that region of the tissue. Stated differently, in a formed lesion or treated area, the low frequency (α region) impedance is about equal to the high-frequency (β region) impedance. Thus, comparison of the low frequency (α region) impedance and the high-frequency (β region) impedance can be used to determine lesion formation in that area of tissue due to focal ablation/cell membrane disruption treatment.

In some embodiments, the systems and devices can be configured to detect a focal ablation or cell membrane disruption in treatment area by simultaneously measuring both a region and β region impedance in a tissue. The systems and devices described herein can be configured to monitor, in real-time, the size of a treated area during a focal ablation or cell membrane disruption procedure. The devices and systems can contain an electrical conductivity sensor, which can contain an impedance sensor or impedance sensor array. The electrical conductivity sensor can be configured to measure both low-frequency (α region) impedance and high-frequency (β region) impedance. The electrical conductivity sensor can be integrated with or operatively coupled to an electrical conductivity probe and/or be integrated with or operatively coupled to a treatment probe.

Electrical Conductivity Sensors

With a general description in mind, attention is directed to FIGS. 1-8, which show embodiments of electrical conductivity sensors that can be configured to measure tissue impedance, a change in tissue impedance between points in a tissue, migration of a lesion/treated area front, and/or both low-frequency (α region) impedance and high-frequency (β region) impedance.

Discussion begins with FIG. 1, which shows one embodiment of an electrical conductivity sensor 100 that can be configured to measure a change in tissue impedance between points in a of tissue, and/or both low-frequency (α region) impedance and high-frequency (β region) impedance. The electrical conductivity sensor 100 can have an impedance sensor 110 at least two electrical conductors 120a,b (collectively 110). In some embodiments, the impedance sensor 110 can have an even number of electrical conductors 120. In some embodiments the impedance sensor 110 can have 2, 3, 4, 5, 6, 7, 8, 9, 10 or more electrical conductors 120. In some embodiments, the impedance sensor 110 can be configured to measure impedance using a bipolar configuration of electrodes 120 (see e.g. FIG. 1). In other embodiments, the impedance sensor 110 can be configured to measure impedance using a tetrapolar configuration (see e.g. FIG. 3). It will be appreciated that the sensor electrodes, in any given configuration, can be separate from any source and sink electrodes that can be used for delivering the focal ablation/cell membrane disruption therapy.

The electrical conductors 120 can be coupled to bonding pads 140a,b (collectively 140). In some embodiments, each electrical conductor 120 is coupled to an individual bonding pad 140. The electrical conductors 120 can be coupled to the bonding pad(s) 140 via electrical leads 150a,b (collectively 150). The electrical conductor 120, the bonding pad(s) 140, and the lead(s) 150 can be coupled to a substrate 160. In some embodiments, the electrical conductors 120 can be coupled to an impedance sensor substrate 130. The impedance sensor substrate 130 can be coupled to the substrate 160. In some embodiments, the electrical conductors 120 can be attached directly to the substrate 160. The electrical conductivity sensor 100 can be configured such that at least a portion of one or more of the electrodes is exposed to the tissue when in use.

The electrical conductivity sensor 100 can have a length (I), a width (w), and a thickness. The length can range from about 1 mm to 1000 mm or more. The width can range from about 0.1 mm to about 50 mm or more. The thickness can range from about 0.1 micron to about 1000 microns or more.

As shown in FIG. 2, the electrical conductivity sensor 100 can be flexible. The substrate 160 and the optional impedance sensor substrate 130 can be made out of any suitable material. The material can be biocompatible. Suitable materials include, but are not limited to ceramics (porcelain, alumina, hydroxyapatite, zirconia), polymers (e.g. thermoplastic elastomers (e.g. silicone elastomers, styrene block copolymers, thermoplastic copolyesters, thermoplastic polyesters, thermoplastic polyamides, thermoplastic polyolefins, thermoplastic polyurethanes, thermoplastic vulcanizates), polyvinyl chloride, fluoropolymers (PTFE, modified PTFE, FEP, ETE, PFA, MFA), polyurethane, polycarbonate, silicone, acrylics, polypropylene, low density polyethylenes, nylon, sulfone resins, high density polyethylenes, natural polymers (cellulose, rubber, alginates, carrageenan), polyimide, polyether ether ketone), metals (e.g. gold, silver, titanium, platinum), metal alloys (e.g. stainless steel, cobalt alloys, titanium alloys), glass, and combinations thereof.

The leads 150, bonding pads 140 and electrical conductors 120 can be made of a suitable conductive or semi-conductive material. The material can be flexible. The materials can be biocompatible. Suitable conductive and semi-conductive materials include, without limitation, gold, silver, copper, aluminum, nickel, platinum, palladium, zinc, molybdenum, tungsten, graphite, Indium tin oxide, conductive organic polymers (e.g. polyacetylene, polyphenylene vinylene, polypyrrole, polythiophene, polyaniline, and polyphenylene sulfide), silicon, germanium, cadmium, indium, and combinations thereof.

In operation, a known electrical current can be passed through at least one of the electrical conductors 120. A voltage is then induced in at least one of the other electrical conductors 120 As such, in embodiments, where there are only two electrical conductors 120 (a bipolar configuration) (see e.g. FIG. 1), a known current can be passed through one electrical conductor (120a) and a voltage is then induced in the other electrical conductor (120b). As shown in FIG. 3, where there are more than two electrical conductors 120a-d (e.g. a tetrapolar configuration), a current can be passed through the outer most electrical conductors 120a,d and the induced voltage across the inner electrical conductors 120b,c can be measured. Other suitable configurations will be appreciated by those of skill in the art. In any embodiment, the high-frequency and low frequency impedance can be measured from the induced voltages. As described elsewhere herein, the high-frequency and low-frequency impedance can be used to determine if a particular region of tissue has been treated and/or the area and/or volume of tissue that has been effectively treated.

Some tissues have anisotropic electrical properties, which can be due to the directional growth of the cell. As such, in some instances it is desirable to measure the electrical conductivities in two orthogonal directions. With this in mind, attention is directed to FIG. 4, which shows an embodiment of an electrical conductivity sensor configured to measure both high- and low-frequency impedance in two orthogonal directions.

As shown in FIG. 4, the electrical conductivity sensor can have at least two impedance sensors 110 and 111. The first impedance sensor 110 can have a first set of electrical conductors 120a-d. The second impedance sensor 111 can have a second set of electrical conductors 121a-d. The first 120 and second 121 sets of electrical conductors can be coupled to a substrate 160 and/or impedance sensor substrate 130 such that the first set of electrical conductors 120 and the second set of electrical conductors 121 are orthogonal to each other. In this way, the first 110 and the second 111 impedance sensors can be said to be orthogonal to each other in these embodiments.

While FIG. 4 shows the impedance sensors 110, 111 in a tetrapolar configuration it will be appreciated by those of skill in the art that they can be configured in any suitable manner, for example, as previously described with respect to FIGS. 1-3. Likewise, each impedance sensor 110, 111 can have at least two electrical conductors 120, 121. In some embodiments, each impedance sensor 110,111 can have 3, 4, 5, 6, 7, 8, 9, 10 or more electrical conductors. The impedance sensors 110, 111 can have the same number or a different number of electrical conductors 120, 121 as each other. The dimensions of these embodiments of the electrical conductivity sensor 100 can be as described with respect to FIGS. 1-3 above. The electrical conductivity sensor 100 and components thereof can be made from suitable materials as previously described with respect to FIGS. 1-3. As previously described, each electrical conductor 120, 121, can be coupled to a bonding pad 140a-d and 141a-d via an electrical leads 150a-d and 151a-d. The operation of each set of electrodes 120, 121 to measure impedance can be as described with respect to FIGS. 1-3 above.

FIGS. 1-4 demonstrate embodiments of an electrical conductivity sensor 100 that contain electrical conductors at a single location on the electrical conductivity sensor 100. As described elsewhere herein it can be desirable to measure the size of a treatment area in a tissue during focal ablation/cell membrane disruption therapy. During therapy, the lesion formed will grow in size, and as such, it can be desirable to measure this growth without the need for repositioning the electrical conductivity sensor, or probe that it can be coupled to, during treatment.

With this in mind, attention is directed to FIGS. 5-8 which show embodiments of an electrical conductivity sensor 100 that has a sensor array. The electrical conductivity sensor 100 having a sensor array can be configured to measure impedance. In some embodiments, the electrical conductivity sensor 100 having a sensor array 200 can be configured to detect both high- and low-frequency impedance having an impedance sensor array 200. In some embodiments the sensor array 200 can be configured to detect another tissue characteristic, including but not limited to, pH, temperature, drug concentration, chemical concentration, gas concentration and combinations thereof. As such, in some embodiments, the lesion/treated area front can be determined by measuring these characteristics.

Discussion continues with FIG. 5 which shows one embodiment of an electrical conductivity sensor 100 having an impedance sensor array 200. In the embodiments depicted by FIG. 5, the impedance sensor array 200 has at least two impedance sensors 110a-h. While FIG. 5 shows an impedance sensor array 200 having eight (8) impedance sensors 110, it will be appreciated that the impedance sensor array 200 can have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 16, 17, 18, 19, 20 or more impedance sensors 110. Each impedance sensor 110 can be coupled to a bonding pad 140a-h and a common ground 210 via electrical leads 150a-h and 152a-h. While FIG. 5 shows an impedance sensor array 200 having eight (8) bonding pads 140, it will be appreciated that the impedance sensor array 200 can have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 16, 17, 18, 19, 20 or more bonding pads 140. The dimensions of these embodiments of the electrical conductivity sensor 100 can be as described with respect to FIGS. 1-3 above. The electrical conductivity sensor 100 and components thereof can be made from suitable materials as previously described with respect to FIGS. 1-3. In some embodiments, the electrical conductivity sensor 100 having an impedance sensor array 200 can contain include two current injection electrodes on either end of the electrode array.

Measurement of low-frequency and/or high-frequency impedance of each impedance sensor 110 of the impedance sensor array 200 can be as previously described with respect to FIGS. 1-3. Further, differences in impedance measurements between two or more different impedance sensors 110 of the impedance sensor array 200 can be determined. In this way it is possible to determine the extent of the lesion formed by focal ablation/cell membrane disruption therapy. Stated differently, the change in the electrical impedance of different combinations of impedance sensors 110 of the impedance sensor array 200 can be evaluated and the lesion size, and/or lesion/treated area front can be determined based on the impedance or other tissue characteristic measurements evaluated. This is discussed in greater detail elsewhere herein.

In some embodiments, the sensors 110 can be functionalized with one or more receptor molecules configured to specifically bind a target molecule. This can make the impedance measurement more selective toward identification of certain intracellular substances, including proteins and ions that are released during electroporation. This modification can enhance the capability of the sensor to detect the lesion front.

FIG. 6 shows another embodiment of an electrical conductivity sensor 100 having an impedance sensor array 200. The impedance sensor array 200 has at least two impedance sensors 110a-e. While FIG. 6 shows an impedance sensor array 200 having five (5) impedance sensors 110, it will be appreciated that the impedance sensor array 200 can have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 16, 17, 18, 19, 20 or more impedance sensors 110. Each impedance sensor 110 can be coupled to a bonding pad 140a-e via electrical leads 150a-e. While FIG. 6 shows an impedance sensor array 200 having five (5) bonding pads 140, it will be appreciated that the impedance sensor array 200 can have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 16, 17, 18, 19, 20 or more bonding pads 140. The electrical impedance measured by any combination of impedance sensors can be determined and correlated to the lesion size. The dimensions of these embodiments of the electrical conductivity sensor 100 can be as described with respect to FIGS. 1-3 above. The electrical conductivity sensor 100 and components thereof can be made from suitable materials as previously described with respect to FIGS. 1-3.

FIG. 7 shows further embodiments of an electrical conductivity sensor 100 having an impedance sensor array 200. These embodiments are the same as those described in relation to FIG. 6 except that they further contain a common counter electrode 220. The common counter electrode 220 can be coupled to the substrate 160. The common counter electrode 220 can be coupled to a bonding pad 230 via an electrical lead 240, which both can also be coupled to the substrate 160. In operation, all impedances measured by the impedance sensors 110 of the impedance sensor array 220 can be measured with respect to the common counter electrode 220. It will be appreciated that a common counter electrode can also be used in embodiments described in FIG. 5. The dimensions of these embodiments of the electrical conductivity sensor 100 can be as described with respect to FIGS. 1-3 above. The electrical conductivity sensor 100 and components thereof can be made from suitable materials as previously described with respect to FIGS. 1-3.

FIG. 8 shows further embodiments of an electrical conductivity sensor 100 having an impedance sensor array 200. The impedance sensor array 200 can contain impedance sensors 110 having interdigitated electrodes 300. In embodiments, the impedance sensor can have a pair of electrode sets 310a,b (collectively 310), where each electrode set has an even number of electrodes (e.g. 2, 4, 6, 8, 10 etc.) and can be interdigitated with each other as shown in FIG. 8. This interdigitated configuration can increase the sensitivity of the impedance sensor 110. While not being bound to theory, it is believed that the increase in sensitivity can be attributed to the increased current density across the interdigitated pair of electrode sets 310 relative to a non-interdigitated electrode set.

While FIG. 8 shows an impedance sensor array 200 having five (5) impedance sensors 110, it will be appreciated that the impedance sensor array 200 can have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 16, 17, 18, 19, 20 or more impedance sensors 110. The impedance sensors 110 can be coupled to a substrate 160 as previously described in relation to e.g. FIGS. 5-7. Each impedance sensor 110 can be coupled to a bonding pad 140 via electrical leads 150a-e. While FIG. 8 shows an impedance sensor array 200 having five (5) bonding pads 140, it will be appreciated that the impedance sensor array 200 can have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14, 16, 17, 18, 19, 20 or more bonding pads 140. In some embodiments, the impedance sensors can all be coupled to a common ground 210 as previously described with respect to FIG. 5. In further embodiments, the electrical conductivity sensor 100 having an impedance sensors 110 with interdigitated electrodes 300 can further contain a common counter electrode 230, which can be configured as shown and described with respect to FIG. 7 The dimensions of these embodiments of the electrical conductivity sensor 100 can be as described with respect to FIGS. 1-3 above. The electrical conductivity sensor 100 and components thereof can be made from suitable materials as previously described with respect to FIGS. 1-3.

In some embodiments, the electrical conductivity sensor 100 as described in relation to any of FIGS. 1-8 can further contain one or more additional sensors to measure additional tissue characteristics. Additional sensors include, but are not limited to, pH sensors, temperature sensors, chemical sensors, and gas (e.g. CO₂, NO, O₂) sensors. There can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more additional sensors. The additional sensors can also be configured as an array akin to the impedance sensor array on the electrical conductivity sensor 100. The additional sensor(s) can be coupled to the substrate 160. The additional sensors can be coupled to one or more additional bonding pads via leads as will be appreciated by those of skill in the art.

The electrical conductivity sensor 100 and/or any component(s) thereof as described in relation to any of FIGS. 1-8 can be disposable, reusable, recyclable, biocompatible, sterile, and/or sterilizable.

The electrical conductivity sensor 100 and components thereof described herein can be manufactured by any suitable method and in any suitable way. Suitable methods include, but are not limited to, injection molding, 3-D printing, glass/plastic molding processes, optical fiber production process, casting, chemical deposition, electrospinning, machining, die casting, evaporative-pattern casting, resin casting, sand casting, shell molding, vacuum molding, thermoforming, laminating, dip molding, embossing, drawing, stamping, electroforming, laser cutting, welding, soldering, sintering, bonding, composite material winding, direct metal laser sintering, fused deposition molding, photolithography, spinning, metal evaporation, chemical etching and sterolithography. Other techniques will be appreciated by those of skill in the art.

Electrical Conductivity Probes

The electrical conductivity sensors 100 described in relation to FIGS. 1-8 can be coupled to or integrated with a probe. In some embodiments, the probe can be a treatment probe (i.e. the probe delivering the focal ablation/cell membrane disruption therapy). The probe that contains the electrical conductivity sensor 100 can be separate from the treatment probe. With the general concept in mind, attention is directed to FIGS. 9-11, which show various embodiments of probes including electrical conductivity sensors 100 as described in relation to FIGS. 1-8. As shown in FIGS. 9-11, which show embodiments of an electrical conductivity probe 400 having one or more electrical conductivity sensor 100a,b,c (collectively 100). The electrical conductivity sensor(s) 100 can be any electrical conductivity sensor described in relation to FIGS. 1-8.

The electrical conductivity probe 400 can have an elongated member 410 having a distal portion 420 and a proximal portion 430. The elongated member 400 can be any three dimensional shape, including but not limited to, an irregular shape, a cylinder, a cannula, a cuboid, and a triangular prism. The elongated member 400 can have a width. The width can range from about 0.1 mm to about 10 mm or more. The elongated member can have a length. The length can range from about 5 mm to about 50 cm or more. The elongated member can have a diameter. The diameter can range from about 10 microns to about 10 mm or more. The distal portion can have a tapered, beveled, pointed, blunt, sharp, rounded, or flat end. Other configurations for the elongated member will be appreciated by those of skill in the ar. At least one electrical conductivity sensor 100a,b,c (collectively 100) coupled to or otherwise integrated with an outer surface of the elongated member. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more electrical conductivity sensors 100 can be coupled to the elongated member 410. In some embodiments the electrical conductivity sensor(s) 100 can be removably coupled to the elongated member 410. The electrical conductivity sensor(s) 100 can be electrically coupled to the elongated member 410. The electrical conductivity sensor(s) 100 can be coupled to the elongated member in any desired configuration, e.g. linearly, radially, and the like, as will be appreciated by those of skill in the art.

The electrical conductivity probe 400 can include sensors configured to detect tissue characteristics (e.g. pH, temperature, chemical, gas sensors) and circuitry as needed. In some embodiments, the electrical conductivity probe 400 can be configured to deliver an energy to result in focal ablation/cell membrane disruption in a tissue. Stated differently, the electrical conductivity probe 400 can also be a treatment probe in some embodiments. In other embodiments, the electrical conductivity probe 400 can be separate from a treatment probe. The electrical conductivity probe 400 and/or components thereof can be disposable, reusable, recyclable, biocompatible, sterile, and/or sterilizable.

In some embodiments, the impedance sensors and impedance sensor arrays can be integrated directly with an elongated member 510 of an electrical conductivity probe 500. In other words, the impedance sensor and impedance sensor arrays and associated circuitry are not coupled to a substrate (e.g. 160, FIGS. 1-8), but rather directly integrated with an elongated member 510 of a probe. With this in mind attention is directed to FIGS. 12-13, which show embodiments of an electrical conductivity probe 500 having one (FIG. 12) or more (FIG. 13) impedance sensors 110, which can be configured to measure tissue impedance, a change in tissue impedance across regions of tissue, and/or both low-frequency (α region) impedance and high-frequency (β region) impedance. The impedance sensor(s) can be as described in relation to any of FIGS. 1-8. As shown in FIG. 13, the impedance sensor(s) can be positioned on the elongated member such that they can form an impedance sensor array 540. The elongated member can be as described in relation to FIGS. 9-11.

The impedance sensor(s) 110 can be electrically coupled to the elongated member 410. The electrical conductivity probe 500 can include additional sensors (e.g. pH, temperature, chemical, gas sensors) and additional circuitry as needed. In some embodiments, the electrical conductivity probe 500 can be configured to deliver an energy to result in focal ablation/cell membrane disruption in a tissue. Stated differently, the electrical conductivity probe 500 can also be a treatment probe in some embodiments. In other embodiments, the electrical conductivity probe 500 can be separate from a treatment probe. The electrical conductivity probe 500 and/or components thereof can be disposable, reusable, recyclable, biocompatible, sterile, and/or sterilizable.

The electrical conductivity probes 400,500 described herein can be manufactured by any suitable method and in any suitable way. Suitable methods include, but are not limited to, injection molding, 3-D printing, glass/plastic molding processes, optical fiber production process, casting, chemical deposition, electrospinning, machining, die casting, evaporative-pattern casting, resin casting, sand casting, shell molding, vacuum molding, thermoforming, laminating, dip molding, embossing, drawing, stamping, electroforming, laser cutting, welding, soldering, sintering, bonding, composite material winding, direct metal laser sintering, fused deposition molding, photolithography, spinning, metal evaporation, chemical etching and sterolithography. Other techniques will be appreciated by those of skill in the art.

Real-Time Lesion/Treated Area Monitoring Systems

Also provided herein are lesion and treated area monitoring systems that can include one or more electrical conductivity probes and components thereof described in relation to FIGS. 1-13 that can monitor lesion formation during focal ablation/cell membrane disruption therapy. Discussion of the various systems begins with FIG. 13, which shows embodiments of a real-time lesion monitoring system 600. An electrical conductivity probe 610 can be coupled to an impedance analyzer 620. The electrical conductivity probe 610 can be any electrical conductivity probe as described in relation to FIGS. 9-13. The impedance analyzer 620 can be electrically coupled to the impedance sensor(s) 110 of the electrical conductivity probe 610. In some embodiments, the impedance analyzer can contain one or more switches 630, where each switch can be coupled to a single impedance sensor on the electrical conductivity probe 610.

The impedance analyzer 620 can include or be coupled to one or more current injection electrodes 640 configured to inject a low voltage (0.1-1000 mV or more) signal into the impedance sensor(s) 110 of the electrical conductivity probe 610. The injection electrode(s) 640 can each be coupled to an impedance sensor 110 via a switch. Not all of the impedance sensors need be coupled to an injection electrode 640. Stated differently, in some embodiments, only some of the impedance sensors are coupled to an injection electrode via a switch. In some embodiments, the injection electrodes 641a,b are separate from the impedance sensor(s) 110 and can be placed on the outside of an impedance sensor array 200. (see e.g. FIG. 13). The impedance analyzer and/or injection electrodes can be coupled to a low voltage power supply 650.

The impedance analyzer 620 can be coupled to and/or in communication with a computer or other data storage/processing device 660. The impedance analyzer 620 can be wirelessly coupled to the computer 660. The impedance analyzer can be hard wired to the computer 660. The computer 660 can contain processing logic configured to analyze data from the impedance analyzer 620 or other sensor information received from the electrical conductivity probe 610 and determine the size of the lesion or treated area 730 in the tissue 740. The computer 660 can contain processing logic configured to generate or initiate a signal (visual, audible, digital or otherwise) to alert a user that the lesion or treated are has reached a threshold size. The computer 660 can contain processing logic that can be configured to analyze data received from the impedance analyzer 620 and/or electrical conductivity probe 610 can contain processing logic configured to analyze data from the impedance analyzer 620 or other sensor information received from the electrical conductivity probe 610 and generate an electrical tomographic image of the treatment area. In some embodiments, the processing logic can be configured to determine the ratio of low-frequency impedance to high frequency impedance at a given impedance sensor 110 from impedance sensor data received from the impedance analyzer 620 and/or electrical conductivity probe 610. The computer 660 can contain processing logic configured to determine the amount of high voltage that should be applied to the treatment area via a treatment probe 670 in response to the impedance data and/or other sensory information received.

The computer 660 can be coupled to a waveform generator 680. The waveform generator 680 can be coupled to a gate driver 690. The gate driver 690 and/or impedance analyzer 620 can be coupled to a high voltage switch 700. The high voltage switch can be coupled to an energy storage device 710. The energy storage device can be coupled to a high voltage power supply 720, configured to deliver a high voltage that can range from 50 to 10000 V or more. A treatment probe 670 can be coupled to the high voltage switch 700. The high voltage switch 700 can be controlled by and/or responsive to the waveform generator 680 and/or gate driver 690. Insofar as the waveform generator 680 and/or gate driver 690 can be controlled by the computer 660, treatment can be, in some embodiments, autonomously controlled in response to impedance and other sensory data obtained by the electrical conductivity probe 610 during treatment. The operation of the system is discussed in further detail below.

In some embodiments, such as those shown in FIG. 15, the electrical conductivity sensor only includes one sensing area as opposed to an array of sensors which provides ease of fabrication and could be used to tell if the lesion front has reached a certain point rather than monitoring its location. The system 800 can be configured the same as that described in relation to FIG. 13, except that a single probe 750, which can contains one or more impedance sensor or an impedance sensor array, is coupled to both the high voltage switch 700 and the low voltage power supply 650.

Real-Time Lesion Front/Treated Area Monitoring

The devices and systems described herein can be used to monitor the lesion formation/front and/or treated area during focal ablation/cell membrane disruption therapies, which include, but are not limited to radiofrequency (RF) ablation, microwave ablation, laser ablation, cryo-ablation, ultrasound, electroporation (reversible and irreversible), supraporation, and radiation therapy. Thus, these devices and systems have application for tumor and undesired ablation, drug delivery, and gene therapy and nucleic acid and other molecule delivery. In principle, an electrical conductivity probe as described in relation to FIGS. 1-13 can be inserted into a tissue. During focal ablation or cell membrane disruption, the treated portion of the tissue undergoes changes due to changes in the permeability of the cell membrane. This results in the formation of a lesion or treated area (e.g. area of tissue to which a drug or other molecule has been delivered). As treatment continues the size of the lesion or treated area can grow. Impedance and other sensors on the electrical conductivity probe can measure electrical conductivity, pH, temperature, chemicals, and/or gasses at locations in the tissue. The systems and devices described herein can then determine the lesion size based upon the electrical conductivity data and other sensory information determined by the probe. In some embodiments, the system can be configured to autonomously control the treatment probe such that when the lesion has reach a desired size, the system can stop treatment in the tissue. In embodiments, the system can be configured to alert a user that the lesion/treated are has reached a desired size. In some embodiments, a user can alter treatment in response to the determined lesion/treated area size. The operation of the systems and devices is discussed in greater detail with respect to FIGS. 16A-17C.

Discussion of the operation of the systems and devices begins with FIGS. 16A-16B, which show monitoring of a lesion/treated area formation and front using an electrical conductivity probe having an impedance sensor during treatment (FIG. 16A) and at the treatment endpoint (FIG. 16B). The treatment probe is not shown in FIGS. 16A and 16B for clarity. However, it will be appreciated that treatment may be provided by a separate treatment probe or be provided by the electrical conductivity probe, which can be configured to deliver high voltage treatment as well as measure tissue characteristics. FIGS. 16A-16B demonstrate monitoring of lesion/treated area formation and front during treatment when using a single impedance sensor (or other sensor) or multiple impedance sensors (or other sensors) placed radially about the surface of the probe such that the sensors are all at the same point along the length of the probe.

As shown in FIG. 16A, the electrical conductivity probe 900 can be inserted into the tissue 910. The electrical conductivity probe 900 can be inserted into the tissue such that the impedance or other sensor is at the outer edge of the desired treatment area. As treatment begins, a lesion or treated area 920 begins to form as the permeability of the cell membranes change. During this time impedance and/or other tissue characteristics are being measured by the sensor(s) 930 on the electrical conductivity probe. The sensors (impedance or other types) can be as described in relation to FIGS. 1-8. As such, during treatment, the impedance and/or other tissue characteristics can be continually determined during treatment and compared to prior measurements, including any baseline measurements taken prior to the start of treatment, to determine if the lesion/treated area has reached the desired size. As shown in FIG. 16B, when the lesion/treated area has grown such that it reaches the point in the tissue where the impedance or other sensor(s) 930 is located, the sensor(s) will measure a change in electrical conductivity and/or pH, chemical concentration, gas concentration, or other molecule concentration and the system can alert a user that the size of the lesion/treated area has reached the desired size. For example, in some embodiments, when the lesion/treated area reaches the sensor(s) 930 on the electrical conductivity probe 900, the low-frequency impedance is equal to the high-frequency impedance. In other embodiments, the system can automatically stop treatment via the treatment probe in response to a detected change in the impedance or other tissue characteristic.

While systems and devices employing sensor(s) at a single point along the length of the probe can be suitable for some applications, they can only determine the size of a lesion/treated area when it reaches a single point. With that in mind attention is directed to FIGS. 17A-17C, which show the operation of an electrical conductivity probe having a sensor array (e.g. an electrical impedance sensor array) during treatment. The treatment probe is not shown in FIGS. 17A-17B for clarity. However, it will be appreciated that treatment may be provided by a separate treatment probe or be provided by the electrical conductivity probe, which can be configured to deliver high voltage treatment as well as measure tissue characteristics.

As shown in FIG. 17A, the electrical conductivity probe 900 can be inserted in a tissue 910 to be treated. Baseline impedance and other tissue characteristic measurements can be obtained prior to the start of treatment. As treatment begins a lesion/treated area 920 can form in the tissue 910. During treatment the sensors of the sensor array 940 can be measuring impedance and/or other tissue characteristics (e.g. pH, chemical concentration, gas concentration, temperature, other molecule concentration, and the system (not shown for clarity) can be determining if there is a change in the impedance and/or other tissue characteristics at any given sensor along the sensor array 940 or between any combination of sensors along the sensor array 940. As the lesion front/treatment area 920 grows (see FIG. 17B), the system will determine that there is a change relative to base line and/or that of another sensor in the impedance and/or other tissue characteristic between certain sensors within the array. From that data the system can determine the size of the lesion and/or determine the position of the lesion front as the lesion grows during treatment. For example, as shown in FIG. 17B the lesion/treated area 920 has grown such that the lesion front is between the second 950b and third sensor 950c of the sensor array 940. As such, the system can determine that there is a change in the impedance (or other tissue characteristic) at the second sensor 950b relative to baseline. The system can determine that there is no change in the impedance (or other tissue characteristic) at the third sensor 950c relative to baseline. From this, the system can determine that the lesion front/treated area has reached the position on the probe that lies between the second 950b and third 950c sensor on the electrical conductivity probe 900. The process of continually measuring impedance (other tissue characteristic) by the sensors of the sensor array 940 and comparing them to baseline/and or other data from other sensors of the sensor array 940 can continue until the lesion/treated area 920 has reached a desired size. The desired size can be predetermined and the system can be configured to alert a user via a signal when the system calculates that the desired size has been reached. In other embodiments, the system can be configured to automatically stop treatment when the system calculates that the desired size has been reached.

It will be appreciated that any number of electrical conductivity probes 900 can be used at the same time. By placing electrical conductivity probes 900 at different locations and depths into the tissue, the data provided can be used by the system to determine a volume of the lesion/treated area and/or generate a three dimensional image of the treated area.

EXAMPLES

Now having described the embodiments of the present disclosure, in general, the following Examples describe some additional embodiments of the present disclosure. While embodiments of the present disclosure are described in connection with the following examples and the corresponding text and figures, there is no intent to limit embodiments of the present disclosure to this description. On the contrary, the intent is to cover all alternatives, modifications, and equivalents included within the spirit and scope of embodiments of the present disclosure.

Example 1

FIGS. 18-20 show images demonstrating an electrical conductivity sensor as described in relation to any of FIGS. 1-8. The fabricated probe is about 15 micron thick, 8 cm long and 8 mm wide. The gold wires are sandwiched between two polyimide layers. The polyimide layer over the bonding pads and the sensor area is removed to expose these parts. The small dimensions of the sensor can enable conductivity measurement with a high spatial resolution. The electrical conductivity sensor can be wrapped around a probe, such as an irreversible electroporation probe (IRE) or other treatment probe to create a device capable of both treating tissue with electroporation and monitoring the extent of the treatment in real-time. In this probe, the conductivity measurement can be conducted at one point next to the beginning of the exposed area of the IRE probe. The electrode can be flexible enough to be easily wrapped around IRE probes with a small diameter of 1 mm. FIG. 21 shows an image of an electrical conductivity sensor that has been coupled to an IRE probe.

Example 2

FIGS. 22A-22J demonstrate a fabrication process for the construction of the electrical conductivity sensor of Example 1. A 4″ Si wafer 2200 was used as the fabrication substrate. The wafer edge was treated with a solution of adhesion promoter (HD Microsystems, Parlin, N.J.) to provide adhesion between the wafer 2200 and the polyimide layer 2210 (FIG. 22B). The adhesion should be enough to keep the construct on the wafer 2200 during the fabrication steps. (FIG. 22B) Polyimide (HD Microsystems, Parlin, N.J.) substrate 2210 was spun and cured over the Si wafer 2200. The spin speed was adjusted to achieve a thickness of about 15 microns. The spin step could be repeated if a greater film thickness is desired. (FIG. 22C) A layer of about 300 nm of gold was deposited on the polyimide layer by PVD. For a better adhesion of gold to the polyimide substrate a Cr layer 2200 was deposited first. (FIG. 22C) A photoresist layer 2230 was spun and patterned as the desired gold electrodes using the photolithography techniques. FIG. 22D The patterned photoresist was used as a mask for wet etching of gold in the next step. Gold and Cr layers were etched 2240 (FIG. 22E) using appropriate wet etching solutions and the photoresist layer 2230 was washed away. Another layer of polyimide 2250 was spun and cured to act as an insulator over the electrode FIG. 22F. The insulator should cover the wires of the electrode and leave the sensor and bond pads exposed. A Ti mask 2260 was deposited by PVD and patterned by photolithography techniques followed by wet etching (FIG. 22G). The Ti mask was used to etch the upper polyimide layer in RIE (Reactive Ion Etching) to expose 2270 the sensing areas and bond pads (FIG. 22H). The Ti mask was washed away using wet etching (FIG. 22I). The whole electrode structure was peeled off the Si wafer 2200 (FIG. 22J). To protect the impedance electrodes from high voltage electric discharge of the pulsing leads, a thin passivation layer such as silicon dioxide or silicon nitride can be coated on the sensor area. This passivation layer acts as a capacitor which protects the sensor from high voltage of the DC pulses however has a minimal impact on the AC impedance readings. Functionalization of the sensors with receptor molecules configured to specifically bind a target molecule can performed after metal patterning as an option using techniques known in the art.

Example 3

A three dimensional finite element model was constructed in Comsol 4.2a (Burlington, Mass.) to simulate IRE treatment of liver tissue with two needle electrodes (FIGS. 23A-23B). The electric potential distribution within the tissue was obtained by transiently solving:

0=−∇·(σ(|E|)∇ϕ) (Equation 1)

Where ϕ is the electric potential, E is the electric field, and a is the electric conductivity. Equation 1 is obtained from Maxwell's equations assuming no external current density (J=σE), no remnant displacement (D=ε₀ε_r,E), and the quasi-static approximation. This approximation implies a negligible coupling between the electric and magnetic fields (∇×E=0), which allows for the expression of electric field only in terms of electric potential:

E=−∇ϕ (Equation 2)

As depicted in Equation 1, the electric conductivity is a function of the electric field magnitude. This equation is used to describe the nonlinear of effects of pore formation in the cell membrane at the tissue scale. Specifically, this can be described by a step function with a certain degree of smoothing, or by other functions that follow similar relationships between the electric conductivity and electric field, such as sigmoid or Gompertz functions. The step function chosen here increased from a baseline conductivity of 0.3 S/m to a plateau of 1.05 S/m across a transition zone of 500 V/cm centered at 500 V/cm. Therefore, regions of tissue subject to an electric field above 750 V/cm were maximally electroporated.

An electric potential boundary condition of 1500 V was applied along the energized surface of one of the electrodes, with the corresponding ground portion of the alternate electrode set to 0 V. The dielectric properties of the exposed portion of the electrodes for performing IRE and the insulative portion for protecting healthy tissue can be found in Garcia, P. A., et al., Intracranial Nonthermal Irreversible Electroporation: In Vivo Analysis. Journal of Membrane Biology, 2010. 236(1): 127-136. All remaining interior boundaries were treated as continuity, and all remaining outer boundary conditions were treated as electrical insulation. The stationary problem consisting of 100,497 mesh elements was solved using an iterative, conjugate gradient solver.

The electrical conductivity in the tissue resulting from IRE is shown in FIG. 24A. Experimentally, voltage drop measurements made between any combination of sensing electrodes can be used to determine this conductivity. Through comparisons to electrical measurements made prior to treatment, it is then possible to determine the extent to which tissue adjacent to each of the sensors has undergone electroporation. If impedance measurements are obtained between electroporative pulses of a multiple pulse protocol, then a real-time, dynamic representation of how the treated tissue expands along the length of the electrode can be obtained. Point specific measurements can also be extrapolated in three dimensions to determine the spatial-temporal conductivity map and electric field distribution (FIG. 24B).

Example 4

FIGS. 25A-27 describe results of delivering a series of high-frequency irreversible electroporation (HFIRE) pulses to porcine liver through the high voltage portion of a probe that also contains an impedance sensor array. FIG. 25A shows an experimental probe model with 5 microelectrodes and 4 sensing pairs (SP). In FIG. 25B, TTC Stained HFIRE ablation in liver (2000 V) can be observed in which viable tissue was stained red while dead tissue whitened. Ablation (marked by dotted line) reached only SP1. The impedance signature throughout delivery of HFIRE pulses as measured by SP1 is shown in FIG. 26). The largest change in impedance was observed at 5 khz, which indicated current was no longer confined to extracellular pathways and its flowing through the cell membrane—indicating electroporation of tissue. This progressive decline in resistance can be used to monitor ablation growth throughout the therapy. FIG. 27 presents the resulting changes in tissue impedance during HFIRE therapy at 5 khz. Major changes in impedance were only observed on probe pair in contact with treated tissue (FIG. 25B). FEM results for electric field distribution along the length of the probe for different pulse parameters can be correlated to these spatio-temporal changes in electrical conductivity during IRE procedures to indicate the electric field threshold for cell death in a tissue of interest.

Example 5

A real-time visualization tool for monitoring of reversible and irreversible electroporation treatments. Once the threshold for cell death in terms of bulk tissue conductivity has been characterized this information can be used to reconstruct the ablation in 3D. The volume of the ablation geometry can be described in 2D with a Cassini oval plot that has the results from one axis extrapolated into a third dimension.

The Cassini oval is a curve that derives its values based on the distance of any given point, a, from the fixed location of two foci, q₁and q₂, located at (x₁, y₁) and (x₂, y₂). The equation is similar to that of an ellipse, except that it is based on the product of distances from the foci, rather than the sum. This makes the equation for such an oval:

└(x₂−a)²+(y₂−a)²┘=b⁴ (Equation 3)

where b⁴is a scaling factor to determine the value at any given point. For incorporation of this equation into shapes that represent the electric field distribution, it is assumed that the two foci are located at the center of the pulsing electrodes along the length of the probe (e.g., x-axis) at (±x,0).

Here, the parameter a represents the location of the ablation front along the length of an IRE needle. This is used to solve for b giving a complete equation to describe the ablation volume. After the probe is placed, software can record baseline values for impedance along a micro-sensor array. After treatment begins, impedance measurements can be recorded in real-time. The location of the ablation (lesion) front can be determined according to the characteristic conductivity of the tissue of interested after it has been irreversibly electroporated. Finally, this data can be used to calculate the ablation geometry, which can be projected as a 3D isometric view of SMART probe onto ortho-planes from stacked CT images of patient anatomy (FIG. 28A). Similarly, the ablation progression can be observed during treatment at 10 (green), 50 (red), and 100 (blue) pulses in axial (FIG. 28B), sagittal (FIG. 28C), and coronal planes (FIG. 28D). Ultimately this system can provide healthcare professions and other practitioners with real-time feedback of any IRE therapy, by displaying the ablation volume relative to a targeted tumor in medical scans such as MRI, PET, or CT.

Example 6

FIGS. 29A-31C describe parts of the methodology related to determining the location of the ablation front and the resulting geometry of the volume of ablation from a series of irreversible electroporation (IRE) pulses through the high voltage portion of a bipolar probe, also containing an impedance sensor array. FIGS. 29A-29C shows the finite element model (FEM) results for electric field distribution along the length of the probe for IRE pulses with a magnitude of 1500V. The dotted line corresponds to a characterized threshold for cell death dependent of a specific number of pulses (N) (e.g., 10, 30, 100). After the tissue has been treated with several IRE pulses an ablation front can be detected in the form of a change in tissue resistivity at different points along the probe (FIGS. 30A-30C). FIGS. 31A-31C shows the resulting volumes of ablation post IRE treatments 10, 30 and 100 pulses of 1500V.

Lesion growth in the perpendicular direction of the probe is also reflected in the impedance measurement by the probe. For example, it is predicted by FEM model (FIGS. 29A-29C, solid line) and observed in FIGS. 31A-31C that for 30 and 100 pulse treatments, probes 1 and 2 would fall within the lesion. However, the corresponding impedance measurement shows 400% and 500% increase in conductivity for 30 and 100 pulses, respectively. This difference is attributed to the depth of lesion in the perpendicular direction. For the case of 10 pulses of 1500V, the small depth of the lesion in perpendicular direction and the marginal location of probe 2 compared with the lesion, results in 200% relative conductivity for sensors 1-2 measurement. For all treatments, the measurements showing 100% relative conductivity correspond to electrodes completely outside of the lesion.

These experimental results show that device (electroporation leads and micro-electrode array) used during these experiments is not only capable of monitoring the lesion length along the probe, but also gives relevant information regarding its other dimensions. This information when combined with FEM modeling can give accurate shape and size of the lesion.

Example 7

FIG. 32 shows a diagram demonstrating how the electrical connections to a conductivity probe 1000 can be made through conductive flexible silicon pads or any other flexible conductive material or structure that can be installed in the handle and in opposite side of the conductive pads 140. The conductive silicon pads can be connected to the external wires. Upon assembly, the conductive silicon pads come in conformal contact with the gold pads on the conductivity sensor and make the electrical connection.

Example 8

FIG. 33A shows a graph demonstrating the impedance spectrum of porcine liver as measured by the conductivity sensor. Fitting of the spectrum to the equivalent circuit model of tissue reveals critical tissue properties at cellular level which could be used for determination of lesion size during ablation. FIG. 33B shows one example of tissue electric circuit model.

Example 9

FIGS. 34 and 35 demonstrate additional embodiments of a system configured to monitor a lesion/treated area front in real-time. In this embodiment, the high voltage energy for tissue ablation can be delivered to the tissue through a single high voltage probe and a large grounding pad, which can be positioned on the surface of the organ/tissue. Due to electric field concentration around the tip of the high voltage electrode, a spherical lesion can form. The spherical lesion can be monitored using the conductivity sensor as described before.

Claims

1. A system comprising: an electrical conductivity probe, wherein the electrical conductivity probe comprises: an elongated member;an electrical conductivity sensor comprising;an impedance sensor, where the impedance sensor is configured to measure a low-frequency and a high-frequency impedance; anda substrate, where the impedance sensor is coupled to the substrate, wherein the electrical conductivity sensor is removably coupled to the elongated member;a treatment probe configured to deliver an energy to a tissue, where the energy is sufficient to disrupt a cell membrane;an impedance analyzer, where the impedance analyzer is coupled to the electrical conductivity probe;a low voltage power supply, where the low voltage power supply is coupled to the electrical conductivity probe and is configured to deliver a low voltage energy to the electrical conductivity probe;a waveform generator, where the waveform generator is coupled to the low voltage power supply;a gate driver, where the gate driver is coupled to the waveform generator and the low voltage power supply;a high voltage switch, where the high voltage switch is coupled to the treatment probe and the impedance analyzer; anda high voltage power supply, where the high voltage power supply is coupled to the high voltage switch.
2. The system of claim 1, further comprising a computer, wherein the computer is coupled to the impedance analyzer and wherein the computer comprises processing logic configured to determine a position of a lesion or treated area front within a tissue undergoing focal ablation/cell membrane disruption therapy.
3. The system of claim 2, wherein the processing logic is further configured to generate a signal to a user when the position of the lesion or treated area front has reached a predetermined position within the tissue.
4. The system of claim 2, wherein the processing logic is further configured to automatically manipulate the system to adjust or stop treatment of the tissue by the treatment probe when the position of the lesion or treated area front has reached a predetermined position within the tissue.
5. The system of claim 2, wherein the treatment probe is coupled with a grounding pad configured to be located elsewhere in or on a body of a subject being treated.
6. The system of claim 1, wherein the treatment probe and the electrical conductivity probe are probe regions on the same probe.
7. A method of monitoring a lesion, a treated area front, or a size thereof during focal ablation or cell membrane disruption therapy, the method comprising: inserting the electrical conductivity probe of the system of claim 1, into a tissue;inserting the treatment probe of the system of claim 1, into the tissue;applying a treatment to the tissue, wherein the treatment comprises applying said energy to the tissue via the treatment probe;measuring a characteristic of the tissue continuously during the treatment; anddetecting a change in the tissue characteristic;wherein the electrical conductivity probe comprises an impedance sensor array comprising two or more impedance sensors, said two or more impedance sensors include said impedance sensor, and further comprising the step of determining the location of the lesion, or the treated area front or the size thereof by comparing impedance data between the two or more impedance sensors of the impedance sensor array.
8. The method of claim 7, wherein the tissue characteristic is impedance.
9. The method of claim 7, wherein the step of measuring comprises measuring both low-frequency impedance and high-frequency impedance and further comprising, determining that the low-frequency impedance is equal to the high frequency impedance; and further comprising the step of stopping the treatment.
10. The method of claim 7, wherein the tissue characteristic is pH, temperature, a gas concentration, a chemical concentration, a nucleic acid concentration, or a combination thereof.
11. The method of claim 7, wherein the change in the tissue characteristic is detected and further comprising the step of stopping the applied treatment.
12. The method of claim 7, wherein the change in the tissue characteristic is detected and further comprising the step of alerting a user of the detected change in the tissue characteristic.
13. The method of claim 7, further comprising the step of comparing the lesion or the treated area front, or size thereof to a threshold value and stopping the applied treatment when the lesion or the treated area front or size is greater than or equal to the threshold value.
14. The method of claim 7, further comprising the step of comparing the lesion or the treated area front, or size thereof to a threshold value and alerting a user when the lesion or the treated area front or size is greater than or equal to the threshold value.
15. The method of claim 7, further comprising the steps of comparing measured changes in impedance to a solution for an electric field distribution during focal ablation or cell membrane disruption and determining a 2D/3D lesion or a 2D/3D treated area geometry of the lesion or the treated area front.
16. The method of claim 15, further comprising the step of overlaying the 2D/3D lesion or treated area geometry on one or more medical images of a subject to generate an image overlay.
17. The method of claim 16, further comprising the step of visualizing migration, growth, or both of the lesion or the treatment area front from the image overlay.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is the 35 U.S.C. § 371 national stage application of PCT Application No. PCT/US2015/065792, filed Dec. 15, 2015, where the PCT claims the benefit of U.S. Provisional Application Ser. No. 62/091,703 filed on Dec. 15, 2014 having the title “Real-Time Monitoring of Electrophysical Effects During Tissue Focal Ablation”, both of which are herein incorporated by reference in their entireties.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under grant number IIP-1026421 awarded by the National Science Foundation. The government has certain rights in the invention.

PCT Information

Filing Document	Filing Date	Country	Kind
PCT/US2015/065792	12/15/2015	WO	00

Publishing Document	Publishing Date	Country	Kind
WO2016/100325	6/23/2016	WO	A

US Referenced Citations (847)

Number	Name	Date	Kind
1653819	Ephraim	Dec 1927	A
3730238	Butler	May 1973	A
3746004	Jankelson	Jul 1973	A
3871359	Pacela	Mar 1975	A
4016886	Doss et al.	Apr 1977	A
4037341	Odle et al.	Jul 1977	A
4216860	Heimann	Aug 1980	A
4226246	Fragnet	Oct 1980	A
4262672	Kief	Apr 1981	A
4267047	Henne et al.	May 1981	A
4278092	Borsanyi et al.	Jul 1981	A
4299217	Sagae et al.	Nov 1981	A
4311148	Courtney et al.	Jan 1982	A
4336881	Babb et al.	Jun 1982	A
4344436	Kubota	Aug 1982	A
4392855	Oreopoulos et al.	Jul 1983	A
4406827	Carim	Sep 1983	A
4407943	Cole et al.	Oct 1983	A
4416276	Newton et al.	Nov 1983	A
4447235	Clarke	May 1984	A
4469098	Davi	Sep 1984	A
4489535	Veltman	Dec 1984	A
4512765	Muto	Apr 1985	A
4580572	Granek et al.	Apr 1986	A
4636199	Victor	Jan 1987	A
4672969	Dew	Jun 1987	A
4676258	Inokuchi et al.	Jun 1987	A
4676782	Yamamoto et al.	Jun 1987	A
4687471	Twardowski et al.	Aug 1987	A
4716896	Ackerman	Jan 1988	A
4723549	Wholey et al.	Feb 1988	A
D294519	Hardy	Mar 1988	S
4756838	Veltman	Jul 1988	A
4772269	Twardowski et al.	Sep 1988	A
4798585	Inoue et al.	Jan 1989	A
4810963	Blake-Coleman et al.	Mar 1989	A
4813929	Semrad	Mar 1989	A
4819637	Dormandy et al.	Apr 1989	A
4822470	Chang	Apr 1989	A
4836204	Landymore et al.	Jun 1989	A
4840172	Augustine et al.	Jun 1989	A
4863426	Ferragamo et al.	Sep 1989	A
4885003	Hillstead	Dec 1989	A
4886496	Conoscenti et al.	Dec 1989	A
4886502	Poirier et al.	Dec 1989	A
4889634	El-Rashidy	Dec 1989	A
4907601	Frick	Mar 1990	A
4919148	Muccio	Apr 1990	A
4920978	Colvin	May 1990	A
4921484	Hillstead	May 1990	A
4946793	Marshall, III	Aug 1990	A
4976709	Sand	Dec 1990	A
4981477	Schon et al.	Jan 1991	A
4986810	Semrad	Jan 1991	A
4987895	Heimlich	Jan 1991	A
5019034	Weaver et al.	May 1991	A
5031775	Kane	Jul 1991	A
5052391	Silberstone et al.	Oct 1991	A
5053013	Ensminger et al.	Oct 1991	A
5058605	Slovak	Oct 1991	A
5071558	Itoh	Dec 1991	A
5098843	Calvin	Mar 1992	A
5122137	Lennox	Jun 1992	A
5134070	Casnig	Jul 1992	A
5137517	Loney et al.	Aug 1992	A
5141499	Zappacosta	Aug 1992	A
D329496	Wotton	Sep 1992	S
5156597	Verreet et al.	Oct 1992	A
5173158	Schmukler	Dec 1992	A
5186715	Phillips et al.	Feb 1993	A
5186800	Dower	Feb 1993	A
5188592	Hakki	Feb 1993	A
5190541	Abele et al.	Mar 1993	A
5192312	Orton	Mar 1993	A
5193537	Freeman	Mar 1993	A
5209723	Twardowski et al.	May 1993	A
5215530	Hogan	Jun 1993	A
5224933	Bromander	Jul 1993	A
5227730	King et al.	Jul 1993	A
5242415	Kantrowitz et al.	Sep 1993	A
5273525	Hofmann	Dec 1993	A
D343687	Houghton et al.	Jan 1994	S
5277201	Stern	Jan 1994	A
5279564	Taylor	Jan 1994	A
5281213	Milder	Jan 1994	A
5283194	Schmukler	Feb 1994	A
5290263	Wigness et al.	Mar 1994	A
5308325	Quinn et al.	May 1994	A
5308338	Helfrich	May 1994	A
5318543	Ross et al.	Jun 1994	A
5318563	Malis et al.	Jun 1994	A
5328451	Davis et al.	Jul 1994	A
5334167	Cocanower	Aug 1994	A
5348554	Imran et al.	Sep 1994	A
D351661	Fischer	Oct 1994	S
5383917	Desai et al.	Jan 1995	A
5389069	Weaver	Feb 1995	A
5391158	Peters	Feb 1995	A
5403311	Abele et al.	Apr 1995	A
5405320	Twardowski et al.	Apr 1995	A
5425752	Vu Nguyen	Jun 1995	A
5439440	Hofmann	Aug 1995	A
5458625	Kendall	Oct 1995	A
5484400	Edwards et al.	Jan 1996	A
5484401	Rodriguez et al.	Jan 1996	A
5533999	Hood et al.	Jul 1996	A
5536240	Edwards et al.	Jul 1996	A
5536267	Edwards et al.	Jul 1996	A
5540737	Fenn	Jul 1996	A
5546940	Panescu et al.	Aug 1996	A
5562720	Stern et al.	Oct 1996	A
5575811	Reid et al.	Nov 1996	A
D376652	Hunt et al.	Dec 1996	S
5582588	Sakurai et al.	Dec 1996	A
5586982	Abela	Dec 1996	A
5588424	Insler et al.	Dec 1996	A
5588960	Edwards et al.	Dec 1996	A
5599294	Edwards et al.	Feb 1997	A
5599311	Raulerson	Feb 1997	A
5616126	Malekmehr et al.	Apr 1997	A
5620479	Diederich	Apr 1997	A
5626146	Barber et al.	May 1997	A
D380272	Partika et al.	Jun 1997	S
5634899	Shapland et al.	Jun 1997	A
5643197	Brucker et al.	Jul 1997	A
5645855	Lorenz	Jul 1997	A
5672173	Gough et al.	Sep 1997	A
5674267	Mir et al.	Oct 1997	A
5683384	Gough et al.	Nov 1997	A
5687723	Avitall	Nov 1997	A
5690620	Knott	Nov 1997	A
5697905	d'Ambrosio	Dec 1997	A
5700252	Klingenstein	Dec 1997	A
5702359	Hofmann et al.	Dec 1997	A
5718246	Vona	Feb 1998	A
5720921	Meserol	Feb 1998	A
5735847	Gough et al.	Apr 1998	A
5752939	Makoto	May 1998	A
5778894	Dorogi et al.	Jul 1998	A
5782882	Lerman et al.	Jul 1998	A
5800378	Edwards et al.	Sep 1998	A
5800484	Gough et al.	Sep 1998	A
5807272	Kun et al.	Sep 1998	A
5807306	Shapland et al.	Sep 1998	A
5807395	Mulier et al.	Sep 1998	A
5810742	Pearlman	Sep 1998	A
5810762	Hofmann	Sep 1998	A
5830184	Basta	Nov 1998	A
5836897	Sakurai et al.	Nov 1998	A
5836905	Lemelson et al.	Nov 1998	A
5843026	Edwards et al.	Dec 1998	A
5843182	Goldstein	Dec 1998	A
5865787	Shapland et al.	Feb 1999	A
5868708	Hart et al.	Feb 1999	A
5873849	Bernard	Feb 1999	A
5904648	Amdt et al.	May 1999	A
5919142	Boone et al.	Jul 1999	A
5919191	Lennox et al.	Jul 1999	A
5921982	Lesh et al.	Jul 1999	A
5944710	Dev et al.	Aug 1999	A
5947284	Foster	Sep 1999	A
5947889	Hehrlein	Sep 1999	A
5951546	Lorentzen	Sep 1999	A
5954745	Gertler et al.	Sep 1999	A
5957919	Laufer	Sep 1999	A
5957963	Dobak	Sep 1999	A
5968006	Hofmann	Oct 1999	A
5983131	Weaver et al.	Nov 1999	A
5984896	Boyd	Nov 1999	A
5991697	Nelson et al.	Nov 1999	A
5999847	Elstrom	Dec 1999	A
6004339	Wijay	Dec 1999	A
6009347	Hofmann	Dec 1999	A
6009877	Edwards	Jan 2000	A
6010613	Walters et al.	Jan 2000	A
6016452	Kasevich	Jan 2000	A
6029090	Herbst	Feb 2000	A
6041252	Walker et al.	Mar 2000	A
6043066	Mangano et al.	Mar 2000	A
6050994	Sherman	Apr 2000	A
6055453	Hofmann et al.	Apr 2000	A
6059780	Gough et al.	May 2000	A
6066134	Eggers et al.	May 2000	A
6068121	McGlinch	May 2000	A
6068650	Hofmann et al.	May 2000	A
6071281	Burnside et al.	Jun 2000	A
6074374	Fulton	Jun 2000	A
6074389	Levine et al.	Jun 2000	A
6085115	Weaver et al.	Jul 2000	A
6090016	Kuo	Jul 2000	A
6090105	Zepeda et al.	Jul 2000	A
6090106	Goble et al.	Jul 2000	A
D430015	Himbert et al.	Aug 2000	S
6096035	Sodhi et al.	Aug 2000	A
6102885	Bass	Aug 2000	A
6106521	Blewett et al.	Aug 2000	A
6109270	Mah et al.	Aug 2000	A
6110192	Ravenscroft et al.	Aug 2000	A
6113593	Tu et al.	Sep 2000	A
6116330	Salyer	Sep 2000	A
6120493	Hofmann	Sep 2000	A
6122599	Mehta	Sep 2000	A
6123701	Nezhat	Sep 2000	A
6132397	Davis et al.	Oct 2000	A
6132419	Hofmann	Oct 2000	A
6134460	Chance	Oct 2000	A
6139545	Utley et al.	Oct 2000	A
6150148	Nanda et al.	Nov 2000	A
6159163	Strauss et al.	Dec 2000	A
6178354	Gibson	Jan 2001	B1
D437941	Frattini	Feb 2001	S
6193715	Wrublewski et al.	Feb 2001	B1
6198970	Freed et al.	Mar 2001	B1
6200314	Sherman	Mar 2001	B1
6208893	Hofmann	Mar 2001	B1
6210402	Olsen et al.	Apr 2001	B1
6212433	Behl	Apr 2001	B1
6216034	Hofmann et al.	Apr 2001	B1
6219577	Brown, III et al.	Apr 2001	B1
D442697	Hajianpour	May 2001	S
6233490	Kasevich	May 2001	B1
6235023	Lee et al.	May 2001	B1
D443360	Haberland	Jun 2001	S
6241702	Lundquist et al.	Jun 2001	B1
6241725	Cosman	Jun 2001	B1
D445198	Frattini	Jul 2001	S
6258100	Alferness et al.	Jul 2001	B1
6261831	Agee	Jul 2001	B1
6277114	Bullivant et al.	Aug 2001	B1
6278895	Bernard	Aug 2001	B1
6280441	Ryan	Aug 2001	B1
6283988	Laufer et al.	Sep 2001	B1
6283989	Laufer et al.	Sep 2001	B1
6284140	Sommermeyer et al.	Sep 2001	B1
6287293	Jones et al.	Sep 2001	B1
6287304	Eggers et al.	Sep 2001	B1
6296636	Cheng et al.	Oct 2001	B1
6298726	Adachi et al.	Oct 2001	B1
6299633	Laufer	Oct 2001	B1
6300108	Rubinsky et al.	Oct 2001	B1
D450391	Hunt et al.	Nov 2001	S
6312428	Eggers et al.	Nov 2001	B1
6326177	Schoenbach et al.	Dec 2001	B1
6327505	Medhkour et al.	Dec 2001	B1
6328689	Gonzalez et al.	Dec 2001	B1
6347247	Dev et al.	Feb 2002	B1
6349233	Adams	Feb 2002	B1
6351674	Silverstone	Feb 2002	B2
6375634	Carroll	Apr 2002	B1
6387671	Rubinsky et al.	May 2002	B1
6398779	Buysse et al.	Jun 2002	B1
6403348	Rubinsky et al.	Jun 2002	B1
6405732	Edwards et al.	Jun 2002	B1
6411852	Danek et al.	Jun 2002	B1
6419674	Bowser et al.	Jul 2002	B1
6428802	Atala	Aug 2002	B1
6437551	Krulevitch et al.	Aug 2002	B1
6443952	Mulier et al.	Sep 2002	B1
6463331	Edwards	Oct 2002	B1
6470211	Ideker et al.	Oct 2002	B1
6482221	Hebert et al.	Nov 2002	B1
6482619	Rubinsky et al.	Nov 2002	B1
6485487	Sherman	Nov 2002	B1
6488673	Laufer et al.	Dec 2002	B1
6488678	Sherman	Dec 2002	B2
6488680	Francischelli et al.	Dec 2002	B1
6491706	Alferness et al.	Dec 2002	B1
6493589	Medhkour et al.	Dec 2002	B1
6493592	Leonard et al.	Dec 2002	B1
6500173	Underwood et al.	Dec 2002	B2
6503248	Levine	Jan 2003	B1
6506189	Rittman et al.	Jan 2003	B1
6514248	Eggers et al.	Feb 2003	B1
6520183	Amar	Feb 2003	B2
6526320	Mitchell	Feb 2003	B2
D471640	McMichael et al.	Mar 2003	S
D471641	McMichael et al.	Mar 2003	S
6530922	Cosman et al.	Mar 2003	B2
6533784	Truckai et al.	Mar 2003	B2
6537976	Gupta	Mar 2003	B1
6540695	Burbank et al.	Apr 2003	B1
6558378	Sherman et al.	May 2003	B2
6562604	Rubinsky et al.	May 2003	B2
6569162	He	May 2003	B2
6575969	Rittman et al.	Jun 2003	B1
6589161	Corcoran	Jul 2003	B2
6592594	Rimbaugh et al.	Jul 2003	B2
6607529	Jones et al.	Aug 2003	B1
6610054	Edwards et al.	Aug 2003	B1
6611706	Avrahami et al.	Aug 2003	B2
6613211	Mccormick et al.	Sep 2003	B1
6616657	Simpson et al.	Sep 2003	B2
6627421	Unger et al.	Sep 2003	B1
D480816	McMichael et al.	Oct 2003	S
6634363	Danek et al.	Oct 2003	B1
6638253	Breznock	Oct 2003	B2
6653091	Dunn et al.	Nov 2003	B1
6666858	Lafontaine	Dec 2003	B2
6669691	Taimisto	Dec 2003	B1
6673070	Edwards et al.	Jan 2004	B2
6678558	Dimmer et al.	Jan 2004	B1
6689096	Loubens et al.	Feb 2004	B1
6692493	Mcgovern et al.	Feb 2004	B2
6694979	Deem et al.	Feb 2004	B2
6694984	Habib	Feb 2004	B2
6695861	Rosenberg et al.	Feb 2004	B1
6697669	Dev et al.	Feb 2004	B2
6697670	Chomenky et al.	Feb 2004	B2
6702808	Kreindel	Mar 2004	B1
6712811	Underwood et al.	Mar 2004	B2
D489973	Root et al.	May 2004	S
6753171	Karube et al.	Jun 2004	B2
6761716	Kadhiresan et al.	Jul 2004	B2
D495807	Agbodoe et al.	Sep 2004	S
6795728	Chornenky et al.	Sep 2004	B2
6801804	Miller et al.	Oct 2004	B2
6812204	McHale et al.	Nov 2004	B1
6837886	Collins et al.	Jan 2005	B2
6847848	Sterzer et al.	Jan 2005	B2
6860847	Alferness et al.	Mar 2005	B2
6865416	Dev et al.	Mar 2005	B2
6881213	Ryan et al.	Apr 2005	B2
6892099	Jaafar et al.	May 2005	B2
6895267	Panescu et al.	May 2005	B2
6905480	James F Mcguckin et al.	Jun 2005	B2
6912417	Bernard et al.	Jun 2005	B1
6927049	Rubinsky et al.	Aug 2005	B2
6941950	Wilson et al.	Sep 2005	B2
6942681	Johnson	Sep 2005	B2
6958062	Gough et al.	Oct 2005	B1
6960189	Bates et al.	Nov 2005	B2
6962587	Johnson et al.	Nov 2005	B2
6972013	Zhang et al.	Dec 2005	B1
6972014	Eum et al.	Dec 2005	B2
6989010	Francischelli et al.	Jan 2006	B2
6994689	Zadno-Azizi et al.	Feb 2006	B1
6994706	Chornenky et al.	Feb 2006	B2
7011094	Rapacki et al.	Mar 2006	B2
7012061	Reiss et al.	Mar 2006	B1
7027869	Danek et al.	Apr 2006	B2
7036510	Zgoda et al.	May 2006	B2
7053063	Rubinsky et al.	May 2006	B2
7054685	Dimmer et al.	May 2006	B2
7063698	Whayne et al.	Jun 2006	B2
7087040	McGuckin et al.	Aug 2006	B2
7097612	Bertolero et al.	Aug 2006	B2
7100616	Springmeyer	Sep 2006	B2
7113821	Sun et al.	Sep 2006	B1
7130697	Chomenky et al.	Oct 2006	B2
7211083	Chomenky et al.	May 2007	B2
7232437	Berman et al.	Jun 2007	B2
7250048	Francischelli et al.	Jul 2007	B2
D549332	Matsumoto et al.	Aug 2007	S
7257450	Auth et al.	Aug 2007	B2
7264002	Danek et al.	Sep 2007	B2
7267676	Chomenky et al.	Sep 2007	B2
7273055	Danek et al.	Sep 2007	B2
7291146	Steinke et al.	Nov 2007	B2
7331940	Sommerich	Feb 2008	B2
7331949	Marisi	Feb 2008	B2
7341558	Torre et al.	Mar 2008	B2
7344533	Pearson et al.	Mar 2008	B2
D565743	Phillips et al.	Apr 2008	S
D571478	Horacek	Jun 2008	S
7387626	Edwards et al.	Jun 2008	B2
7399747	Clair et al.	Jul 2008	B1
D575399	Matsumoto et al.	Aug 2008	S
D575402	Sandor	Aug 2008	S
7419487	Johnson et al.	Sep 2008	B2
7434578	Dillard et al.	Oct 2008	B2
7449019	Uchida et al.	Nov 2008	B2
7451765	Adler	Nov 2008	B2
7455675	Schur et al.	Nov 2008	B2
7476203	DeVore et al.	Jan 2009	B2
7520877	Lee et al.	Apr 2009	B2
7533671	Gonzalez et al.	May 2009	B2
D595422	Mustapha	Jun 2009	S
7544301	Shah et al.	Jun 2009	B2
7549984	Mathis	Jun 2009	B2
7565208	Harris et al.	Jul 2009	B2
7571729	Saadat et al.	Aug 2009	B2
7632291	Stephens et al.	Dec 2009	B2
7655004	Long	Feb 2010	B2
7674249	Ivorra et al.	Mar 2010	B2
7680543	Azure	Mar 2010	B2
D613418	Ryan et al.	Apr 2010	S
7718409	Rubinsky et al.	May 2010	B2
7722606	Azure	May 2010	B2
7742795	Stone et al.	Jun 2010	B2
7765010	Chornenky et al.	Jul 2010	B2
7771401	Hekmat et al.	Aug 2010	B2
RE42016	Chomenky et al.	Dec 2010	E
D630321	Hamilton	Jan 2011	S
D631154	Hamilton	Jan 2011	S
RE42277	Jaafar et al.	Apr 2011	E
7918852	Tullis et al.	Apr 2011	B2
7937143	Demarais et al.	May 2011	B2
7938824	Chornenky et al.	May 2011	B2
7951582	Gazit et al.	May 2011	B2
7955827	Rubinsky et al.	Jun 2011	B2
RE42835	Chomenky et al.	Oct 2011	E
D647628	Helfteren	Oct 2011	S
8048067	Davalos et al.	Nov 2011	B2
RE43009	Chomenky et al.	Dec 2011	E
8109926	Azure	Feb 2012	B2
8114070	Rubinsky et al.	Feb 2012	B2
8162918	Ivorra et al.	Apr 2012	B2
8187269	Shadduck et al.	May 2012	B2
8221411	Francischelli et al.	Jul 2012	B2
8231603	Hobbs et al.	Jul 2012	B2
8240468	Wilkinson et al.	Aug 2012	B2
8251986	Chomenky et al.	Aug 2012	B2
8267927	Dalal et al.	Sep 2012	B2
8267936	Hushka et al.	Sep 2012	B2
8282631	Davalos et al.	Oct 2012	B2
8298222	Rubinsky et al.	Oct 2012	B2
8348921	Ivorra et al.	Jan 2013	B2
8361066	Long et al.	Jan 2013	B2
D677798	Hart et al.	Mar 2013	S
8425455	Nentwick	Apr 2013	B2
8425505	Long	Apr 2013	B2
8454594	Demarais et al.	Jun 2013	B2
8465464	Travis et al.	Jun 2013	B2
8465484	Davalos et al.	Jun 2013	B2
8511317	Thapliyal et al.	Aug 2013	B2
8518031	Boyden et al.	Aug 2013	B2
8562588	Hobbs et al.	Oct 2013	B2
8603087	Rubinsky et al.	Dec 2013	B2
8632534	Pearson et al.	Jan 2014	B2
8634929	Chomenky et al.	Jan 2014	B2
8647338	Chomenky et al.	Feb 2014	B2
8715276	Thompson et al.	May 2014	B2
8753335	Moshe et al.	Jun 2014	B2
8814860	Davalos et al.	Aug 2014	B2
8835166	Phillips et al.	Sep 2014	B2
8845635	Daniel et al.	Sep 2014	B2
8880195	Azure	Nov 2014	B2
8903488	Callas et al.	Dec 2014	B2
8906006	Chomenky et al.	Dec 2014	B2
8926606	Davalos et al.	Jan 2015	B2
8958888	Chomenky et al.	Feb 2015	B2
8968542	Davalos et al.	Mar 2015	B2
8992517	Davalos et al.	Mar 2015	B2
9005189	Davalos et al.	Apr 2015	B2
9078665	Moss et al.	Jul 2015	B2
9149331	Deem et al.	Oct 2015	B2
9173704	Hobbs et al.	Nov 2015	B2
9198733	Neal, II et al.	Dec 2015	B2
9283051	Garcia et al.	Mar 2016	B2
9414881	Callas et al.	Aug 2016	B2
9598691	Davalos	Mar 2017	B2
9867652	Sano et al.	Jan 2018	B2
10117701	Davalos et al.	Nov 2018	B2
10117707	Garcia et al.	Nov 2018	B2
10154874	Davalos et al.	Dec 2018	B2
10238447	Neal et al.	Mar 2019	B2
10245098	Davalos et al.	Apr 2019	B2
10245105	Davalos et al.	Apr 2019	B2
10272178	Davalos et al.	Apr 2019	B2
10286108	Davalos et al.	May 2019	B2
10292755	Davalos et al.	May 2019	B2
20010039393	Mori et al.	Nov 2001	A1
20010044596	Jaafar	Nov 2001	A1
20010046706	Rubinsky et al.	Nov 2001	A1
20010047167	Heggeness	Nov 2001	A1
20010051366	Rubinsky et al.	Dec 2001	A1
20020002393	Mitchell	Jan 2002	A1
20020010491	Schoenbach et al.	Jan 2002	A1
20020022864	Mahvi et al.	Feb 2002	A1
20020040204	Dev et al.	Apr 2002	A1
20020049370	Laufer et al.	Apr 2002	A1
20020052601	Goldberg et al.	May 2002	A1
20020055731	Atala et al.	May 2002	A1
20020065541	Fredricks et al.	May 2002	A1
20020072742	Schaefer et al.	Jun 2002	A1
20020077314	Falk et al.	Jun 2002	A1
20020077676	Schroeppel et al.	Jun 2002	A1
20020082543	Park et al.	Jun 2002	A1
20020099323	Dev et al.	Jul 2002	A1
20020104318	Jaafar et al.	Aug 2002	A1
20020111615	Cosman et al.	Aug 2002	A1
20020112729	DeVore et al.	Aug 2002	A1
20020115208	Mitchell et al.	Aug 2002	A1
20020119437	Grooms et al.	Aug 2002	A1
20020133324	Weaver et al.	Sep 2002	A1
20020137121	Rubinsky et al.	Sep 2002	A1
20020138075	Edwards et al.	Sep 2002	A1
20020138117	Son	Sep 2002	A1
20020143365	Herbst	Oct 2002	A1
20020147462	Mair et al.	Oct 2002	A1
20020156472	Lee et al.	Oct 2002	A1
20020161361	Sherman et al.	Oct 2002	A1
20020183684	Dev et al.	Dec 2002	A1
20020183735	Edwards et al.	Dec 2002	A1
20020183740	Edwards et al.	Dec 2002	A1
20020188242	Wu	Dec 2002	A1
20020193784	McHale et al.	Dec 2002	A1
20020193831	Smith	Dec 2002	A1
20030009110	Tu et al.	Jan 2003	A1
20030016168	Jandrell	Jan 2003	A1
20030055220	Legrain	Mar 2003	A1
20030055420	Kadhiresan et al.	Mar 2003	A1
20030059945	Dzekunov et al.	Mar 2003	A1
20030060856	Chornenky et al.	Mar 2003	A1
20030078490	Damasco et al.	Apr 2003	A1
20030088189	Tu et al.	May 2003	A1
20030088199	Kawaji	May 2003	A1
20030096407	Atala et al.	May 2003	A1
20030105454	Cucin	Jun 2003	A1
20030109871	Johnson et al.	Jun 2003	A1
20030127090	Gifford et al.	Jul 2003	A1
20030130711	Pearson et al.	Jul 2003	A1
20030135242	Mongeon et al.	Jul 2003	A1
20030149451	Chomenky et al.	Aug 2003	A1
20030154988	DeVore et al.	Aug 2003	A1
20030159700	Laufer et al.	Aug 2003	A1
20030166181	Rubinsky et al.	Sep 2003	A1
20030170898	Gundersen et al.	Sep 2003	A1
20030194808	Rubinsky et al.	Oct 2003	A1
20030195385	DeVore	Oct 2003	A1
20030195406	Jenkins et al.	Oct 2003	A1
20030199050	Mangano et al.	Oct 2003	A1
20030208200	Palanker et al.	Nov 2003	A1
20030208236	Heil et al.	Nov 2003	A1
20030212394	Pearson et al.	Nov 2003	A1
20030212412	Dillard et al.	Nov 2003	A1
20030225360	Eppstein et al.	Dec 2003	A1
20030228344	Fields et al.	Dec 2003	A1
20040009459	Anderson et al.	Jan 2004	A1
20040019371	Jaafar et al.	Jan 2004	A1
20040055606	Hendricksen et al.	Mar 2004	A1
20040059328	Daniel et al.	Mar 2004	A1
20040059389	Chomenky et al.	Mar 2004	A1
20040068228	Cunningham	Apr 2004	A1
20040116965	Falkenberg	Jun 2004	A1
20040133194	Eum et al.	Jul 2004	A1
20040138715	Groeningen et al.	Jul 2004	A1
20040146877	Diss et al.	Jul 2004	A1
20040153057	Davison	Aug 2004	A1
20040176855	Badylak	Sep 2004	A1
20040193042	Scampini	Sep 2004	A1
20040193097	Hofmann et al.	Sep 2004	A1
20040199159	Lee et al.	Oct 2004	A1
20040200484	Springmeyer	Oct 2004	A1
20040206349	Alferness et al.	Oct 2004	A1
20040210248	Gordon et al.	Oct 2004	A1
20040230187	Lee et al.	Nov 2004	A1
20040236376	Miklavcic et al.	Nov 2004	A1
20040243107	Macoviak et al.	Dec 2004	A1
20040267189	Mavor et al.	Dec 2004	A1
20040267340	Cioanta et al.	Dec 2004	A1
20050010209	Lee et al.	Jan 2005	A1
20050010259	Gerber	Jan 2005	A1
20050013870	Freyman et al.	Jan 2005	A1
20050020965	Rioux et al.	Jan 2005	A1
20050043726	Mchale et al.	Feb 2005	A1
20050048651	Ryttsen et al.	Mar 2005	A1
20050049541	Behar et al.	Mar 2005	A1
20050061322	Freitag	Mar 2005	A1
20050066974	Fields et al.	Mar 2005	A1
20050143817	Hunter et al.	Jun 2005	A1
20050165393	Eppstein	Jul 2005	A1
20050171522	Christopherson	Aug 2005	A1
20050171523	Rubinsky et al.	Aug 2005	A1
20050171574	Rubinsky et al.	Aug 2005	A1
20050182462	Chornenky et al.	Aug 2005	A1
20050197619	Rule et al.	Sep 2005	A1
20050261672	Deem et al.	Nov 2005	A1
20050267407	Goldman	Dec 2005	A1
20050282284	Rubinsky et al.	Dec 2005	A1
20050283149	Thorne et al.	Dec 2005	A1
20050288684	Aronson et al.	Dec 2005	A1
20050288702	McGurk et al.	Dec 2005	A1
20050288730	Deem et al.	Dec 2005	A1
20060004356	Bilski et al.	Jan 2006	A1
20060004400	McGurk et al.	Jan 2006	A1
20060009748	Mathis	Jan 2006	A1
20060015147	Persson et al.	Jan 2006	A1
20060020347	Barrett et al.	Jan 2006	A1
20060024359	Walker et al.	Feb 2006	A1
20060025760	Podhajsky	Feb 2006	A1
20060074413	Behzadian	Apr 2006	A1
20060079838	Walker et al.	Apr 2006	A1
20060079845	Howard et al.	Apr 2006	A1
20060079883	Elmouelhi et al.	Apr 2006	A1
20060085054	Zikorus et al.	Apr 2006	A1
20060089635	Young et al.	Apr 2006	A1
20060121610	Rubinsky et al.	Jun 2006	A1
20060142801	Demarais et al.	Jun 2006	A1
20060149123	Vidlund et al.	Jul 2006	A1
20060173490	Lafontaine et al.	Aug 2006	A1
20060182684	Beliveau	Aug 2006	A1
20060195146	Tracey et al.	Aug 2006	A1
20060212032	Daniel et al.	Sep 2006	A1
20060212078	Demarais et al.	Sep 2006	A1
20060217703	Chornenky et al.	Sep 2006	A1
20060224188	Libbus et al.	Oct 2006	A1
20060235474	Demarais	Oct 2006	A1
20060247619	Kaplan et al.	Nov 2006	A1
20060264752	Rubinsky et al.	Nov 2006	A1
20060264807	Westersten et al.	Nov 2006	A1
20060269531	Beebe et al.	Nov 2006	A1
20060276710	Krishnan	Dec 2006	A1
20060278241	Ruano	Dec 2006	A1
20060283462	Fields et al.	Dec 2006	A1
20060293713	Rubinsky et al.	Dec 2006	A1
20060293725	Rubinsky et al.	Dec 2006	A1
20060293730	Rubinsky et al.	Dec 2006	A1
20060293731	Rubinsky et al.	Dec 2006	A1
20060293734	Scott et al.	Dec 2006	A1
20070010805	Fedewa et al.	Jan 2007	A1
20070016183	Lee et al.	Jan 2007	A1
20070016185	Tullis et al.	Jan 2007	A1
20070021803	Deem et al.	Jan 2007	A1
20070025919	Deem et al.	Feb 2007	A1
20070043345	Davalos et al.	Feb 2007	A1
20070060989	Deem et al.	Mar 2007	A1
20070078391	Wortley et al.	Apr 2007	A1
20070088347	Young et al.	Apr 2007	A1
20070093789	Smith	Apr 2007	A1
20070096048	Clerc	May 2007	A1
20070118069	Persson et al.	May 2007	A1
20070129711	Altshuler et al.	Jun 2007	A1
20070129760	Demarais et al.	Jun 2007	A1
20070151848	Novak	Jul 2007	A1
20070156135	Rubinsky et al.	Jul 2007	A1
20070191889	Lang	Aug 2007	A1
20070203486	Young	Aug 2007	A1
20070230757	Trachtenberg et al.	Oct 2007	A1
20070239099	Goldfarb et al.	Oct 2007	A1
20070244521	Bomzin et al.	Oct 2007	A1
20070287950	Kjeken et al.	Dec 2007	A1
20070295336	Nelson et al.	Dec 2007	A1
20070295337	Nelson et al.	Dec 2007	A1
20080015571	Rubinsky et al.	Jan 2008	A1
20080021371	Rubinsky et al.	Jan 2008	A1
20080027314	Miyazaki et al.	Jan 2008	A1
20080027343	Fields et al.	Jan 2008	A1
20080033340	Heller et al.	Feb 2008	A1
20080033417	Nields et al.	Feb 2008	A1
20080045880	Kjeken et al.	Feb 2008	A1
20080052786	Lin et al.	Feb 2008	A1
20080065062	Leung	Mar 2008	A1
20080071262	Azure	Mar 2008	A1
20080097139	Clerc et al.	Apr 2008	A1
20080097422	Edwards et al.	Apr 2008	A1
20080103529	Schoenbach et al.	May 2008	A1
20080121375	Richason et al.	May 2008	A1
20080125772	Stone et al.	May 2008	A1
20080132826	Shadduck et al.	Jun 2008	A1
20080132884	Rubinsky et al.	Jun 2008	A1
20080132885	Rubinsky et al.	Jun 2008	A1
20080140064	Vegesna	Jun 2008	A1
20080146934	Czygan et al.	Jun 2008	A1
20080154259	Gough et al.	Jun 2008	A1
20080167649	Edwards et al.	Jul 2008	A1
20080171985	Karakoca	Jul 2008	A1
20080190434	Wai	Aug 2008	A1
20080200911	Long	Aug 2008	A1
20080200912	Long	Aug 2008	A1
20080208052	LePivert et al.	Aug 2008	A1
20080210243	Clayton et al.	Sep 2008	A1
20080214986	Ivorra et al.	Sep 2008	A1
20080236593	Nelson et al.	Oct 2008	A1
20080249503	Fields et al.	Oct 2008	A1
20080262489	Steinke	Oct 2008	A1
20080269586	Rubinsky et al.	Oct 2008	A1
20080269838	Brighton et al.	Oct 2008	A1
20080275465	Paul et al.	Nov 2008	A1
20080281319	Paul et al.	Nov 2008	A1
20080283065	Chang et al.	Nov 2008	A1
20080288038	Paul et al.	Nov 2008	A1
20080300589	Paul et al.	Dec 2008	A1
20080306427	Bailey	Dec 2008	A1
20080312599	Rosenberg	Dec 2008	A1
20090018206	Barkan et al.	Jan 2009	A1
20090024075	Schroeppel et al.	Jan 2009	A1
20090029407	Gazit et al.	Jan 2009	A1
20090038752	Weng et al.	Feb 2009	A1
20090062788	Long et al.	Mar 2009	A1
20090062792	Vakharia et al.	Mar 2009	A1
20090081272	Clarke et al.	Mar 2009	A1
20090105703	Shadduck	Apr 2009	A1
20090114226	Deem et al.	May 2009	A1
20090125009	Zikorus et al.	May 2009	A1
20090138014	Bonutti	May 2009	A1
20090143705	Danek et al.	Jun 2009	A1
20090157166	Singhal et al.	Jun 2009	A1
20090163904	Miller et al.	Jun 2009	A1
20090171280	Samuel et al.	Jul 2009	A1
20090177111	Miller et al.	Jul 2009	A1
20090186850	Kiribayashi et al.	Jul 2009	A1
20090192508	Laufer et al.	Jul 2009	A1
20090198231	Esser et al.	Aug 2009	A1
20090228001	Pacey	Sep 2009	A1
20090247933	Maor et al.	Oct 2009	A1
20090248012	Maor et al.	Oct 2009	A1
20090269317	Davalos	Oct 2009	A1
20090275827	Aiken et al.	Nov 2009	A1
20090281477	Mikus et al.	Nov 2009	A1
20090292342	Rubinsky et al.	Nov 2009	A1
20090301480	Elsakka et al.	Dec 2009	A1
20090306544	Ng et al.	Dec 2009	A1
20090306545	Elsakka et al.	Dec 2009	A1
20090318905	Bhargav et al.	Dec 2009	A1
20090326436	Rubinsky et al.	Dec 2009	A1
20090326570	Brown	Dec 2009	A1
20100004623	Hamilton, Jr. et al.	Jan 2010	A1
20100006441	Renaud	Jan 2010	A1
20100023004	Francischelli et al.	Jan 2010	A1
20100030211	Davalos et al.	Feb 2010	A1
20100049190	Long et al.	Feb 2010	A1
20100057074	Roman et al.	Mar 2010	A1
20100069921	Miller et al.	Mar 2010	A1
20100087813	Long	Apr 2010	A1
20100130975	Long	May 2010	A1
20100147701	Field	Jun 2010	A1
20100152725	Pearson et al.	Jun 2010	A1
20100160850	Ivorra et al.	Jun 2010	A1
20100168735	Deno et al.	Jul 2010	A1
20100174282	Demarais et al.	Jul 2010	A1
20100179530	Long et al.	Jul 2010	A1
20100196984	Rubinsky et al.	Aug 2010	A1
20100204560	Salahieh et al.	Aug 2010	A1
20100204638	Hobbs et al.	Aug 2010	A1
20100222677	Placek et al.	Sep 2010	A1
20100228234	Hyde et al.	Sep 2010	A1
20100228247	Paul et al.	Sep 2010	A1
20100241117	Paul et al.	Sep 2010	A1
20100249771	Pearson et al.	Sep 2010	A1
20100250209	Pearson et al.	Sep 2010	A1
20100255795	Rubinsky et al.	Oct 2010	A1
20100256628	Pearson et al.	Oct 2010	A1
20100256630	Hamilton, Jr. et al.	Oct 2010	A1
20100261994	Davalos et al.	Oct 2010	A1
20100286690	Paul et al.	Nov 2010	A1
20100298823	Cao et al.	Nov 2010	A1
20100331758	Davalos et al.	Dec 2010	A1
20110017207	Hendricksen et al.	Jan 2011	A1
20110034209	Rubinsky et al.	Feb 2011	A1
20110064671	Bynoe	Mar 2011	A1
20110106221	Robert et al.	May 2011	A1
20110112531	Landis et al.	May 2011	A1
20110118727	Fish et al.	May 2011	A1
20110118732	Rubinsky et al.	May 2011	A1
20110130834	Wilson et al.	Jun 2011	A1
20110144524	Fish et al.	Jun 2011	A1
20110144635	Harper et al.	Jun 2011	A1
20110144657	Fish et al.	Jun 2011	A1
20110152678	Aljuri et al.	Jun 2011	A1
20110166499	Demarais et al.	Jul 2011	A1
20110176037	Benkley, III	Jul 2011	A1
20110202053	Moss et al.	Aug 2011	A1
20110217730	Gazit et al.	Sep 2011	A1
20110251607	Kruecker et al.	Oct 2011	A1
20110301587	Deem et al.	Dec 2011	A1
20120034131	Rubinsky et al.	Feb 2012	A1
20120059255	Paul et al.	Mar 2012	A1
20120071872	Rubinsky et al.	Mar 2012	A1
20120071874	Davalos et al.	Mar 2012	A1
20120085649	Sane et al.	Apr 2012	A1
20120089009	Omary et al.	Apr 2012	A1
20120090646	Tanaka et al.	Apr 2012	A1
20120095459	Callas et al.	Apr 2012	A1
20120109122	Arena et al.	May 2012	A1
20120130289	Demarais et al.	May 2012	A1
20120150172	Ortiz et al.	Jun 2012	A1
20120165813	Lee et al.	Jun 2012	A1
20120179091	Ivorra et al.	Jul 2012	A1
20120226218	Phillips et al.	Sep 2012	A1
20120226271	Callas et al.	Sep 2012	A1
20120265186	Burger et al.	Oct 2012	A1
20120277741	Davalos et al.	Nov 2012	A1
20120303020	Chornenky et al.	Nov 2012	A1
20120310236	Placek et al.	Dec 2012	A1
20130030239	Weyh et al.	Jan 2013	A1
20130090646	Moss et al.	Apr 2013	A1
20130108667	Soikum et al.	May 2013	A1
20130110106	Richardson	May 2013	A1
20130184702	Neal, II et al.	Jul 2013	A1
20130196441	Rubinsky et al.	Aug 2013	A1
20130197425	Golberg et al.	Aug 2013	A1
20130202766	Rubinsky et al.	Aug 2013	A1
20130218157	Callas et al.	Aug 2013	A1
20130253415	Sane et al.	Sep 2013	A1
20130281968	Davalos et al.	Oct 2013	A1
20130345697	Garcia et al.	Dec 2013	A1
20130345779	Maor et al.	Dec 2013	A1
20140017218	Scott et al.	Jan 2014	A1
20140039489	Davalos et al.	Feb 2014	A1
20140046322	Callas et al.	Feb 2014	A1
20140066913	Sherman	Mar 2014	A1
20140081255	Johnson et al.	Mar 2014	A1
20140088578	Rubinsky et al.	Mar 2014	A1
20140121663	Pearson et al.	May 2014	A1
20140121728	Dhillon et al.	May 2014	A1
20140163551	Maor et al.	Jun 2014	A1
20140207133	Model et al.	Jul 2014	A1
20140296844	Kevin et al.	Oct 2014	A1
20140309579	Rubinsky et al.	Oct 2014	A1
20140378964	Pearson	Dec 2014	A1
20150088120	Garcia et al.	Mar 2015	A1
20150088220	Callas et al.	Mar 2015	A1
20150112333	Chorenky et al.	Apr 2015	A1
20150126922	Willis	May 2015	A1
20150152504	Lin	Jun 2015	A1
20150164584	Davalos et al.	Jun 2015	A1
20150173824	Davalos et al.	Jun 2015	A1
20150201996	Rubinsky et al.	Jul 2015	A1
20150265349	Moss et al.	Sep 2015	A1
20150289923	Davalos et al.	Oct 2015	A1
20150320488	Moshe et al.	Nov 2015	A1
20150320999	Nuccitelli et al.	Nov 2015	A1
20150327944	Robert et al.	Nov 2015	A1
20160022957	Hobbs et al.	Jan 2016	A1
20160066977	Neal et al.	Mar 2016	A1
20160074114	Pearson et al.	Mar 2016	A1
20160113708	Moss et al.	Apr 2016	A1
20160143698	Garcia et al.	May 2016	A1
20160235470	Callas et al.	Aug 2016	A1
20160287313	Rubinsky et al.	Oct 2016	A1
20160287314	Arena et al.	Oct 2016	A1
20160338761	Chornenky et al.	Nov 2016	A1
20160354142	Pearson et al.	Dec 2016	A1
20160367310	Onik et al.	Dec 2016	A1
20170035501	Chornenky et al.	Feb 2017	A1
20170189579	Davalos	Jul 2017	A1
20170209620	Davalos et al.	Jul 2017	A1
20170266438	Sano	Sep 2017	A1
20170360326	Davalos	Dec 2017	A1
20180071014	Neal et al.	Mar 2018	A1
20180125565	Sano et al.	May 2018	A1
20180161086	Davalos et al.	Jun 2018	A1
20190029749	Garcia	Jan 2019	A1
20190046255	Davalos et al.	Feb 2019	A1
20190069945	Davalos et al.	Mar 2019	A1
20190083169	Single et al.	Mar 2019	A1
20190133671	Davalos et al.	May 2019	A1
20190175248	Neal, II	Jun 2019	A1
20190175260	Davalos	Jun 2019	A1
20190223938	Arena et al.	Jul 2019	A1
20190232048	Latouche et al.	Aug 2019	A1
20190233809	Neal et al.	Aug 2019	A1
20190256839	Neal et al.	Aug 2019	A1
20190282294	Davalos et al.	Sep 2019	A1
20190328445	Sano et al.	Oct 2019	A1
20190351224	Sano et al.	Nov 2019	A1

Foreign Referenced Citations (132)

Number	Date	Country
2002315095	Dec 2002	AU
2003227960	Dec 2003	AU
2005271471	Feb 2006	AU
2006321570	Jun 2007	AU
2006321574	Jun 2007	AU
2006321918	Jun 2007	AU
2297846	Feb 1999	CA
2378110	Feb 2001	CA
2445392	Nov 2002	CA
2458676	Mar 2003	CA
2487284	Dec 2003	CA
2575792	Feb 2006	CA
2631940	Jun 2007	CA
2631946	Jun 2007	CA
2632604	Jun 2007	CA
2751462	Nov 2010	CA
1525839	Sep 2004	CN
101534736	Sep 2009	CN
102238921	Nov 2011	CN
102421386	Apr 2012	CN
86311	Jan 1953	DE
4000893	Jul 1991	DE
60038026	Feb 2009	DE
0218275	Apr 1987	EP
0339501	Nov 1989	EP
0378132	Jul 1990	EP
0533511	Mar 1993	EP
0998235	May 2000	EP
0528891	Jul 2000	EP
1196550	Apr 2002	EP
1439792	Jul 2004	EP
1442765	Aug 2004	EP
1462065	Sep 2004	EP
1061983	Nov 2004	EP
1493397	Jan 2005	EP
1506039	Feb 2005	EP
0935482	May 2005	EP
1011495	Nov 2005	EP
1796568	Jun 2007	EP
1207797	Feb 2008	EP
1406685	Jun 2008	EP
1424970	Dec 2008	EP
2381829	Nov 2011	EP
2413833	Feb 2012	EP
1791485	Dec 2014	EP
2373241	Jan 2015	EP
1962710	Aug 2015	EP
1962708	Sep 2015	EP
1962945	Apr 2016	EP
2300272	Jun 2008	ES
2315493	Apr 2009	ES
2001510702	Aug 2001	JP
2003505072	Feb 2003	JP
2003506064	Feb 2003	JP
2004203224	Jul 2004	JP
2004525726	Aug 2004	JP
2004303590	Oct 2004	JP
2005501596	Jan 2005	JP
2005526579	Sep 2005	JP
2008508946	Mar 2008	JP
4252316	Apr 2009	JP
2009518130	May 2009	JP
2009518150	May 2009	JP
2009518151	May 2009	JP
2009532077	Sep 2009	JP
2010503496	Feb 2010	JP
2011137025	Jul 2011	JP
2011137025	Jul 2011	JP
2012510332	May 2012	JP
2012515018	Jul 2012	JP
2012521863	Sep 2012	JP
101034682	May 2011	KR
9104014	Apr 1991	WO
9634571	Nov 1996	WO
9639531	Dec 1996	WO
9810745	Mar 1998	WO
9814238	Apr 1998	WO
9901076	Jan 1999	WO
9904710	Feb 1999	WO
0020554	Apr 2000	WO
0107583	Feb 2001	WO
0107584	Feb 2001	WO
0107585	Feb 2001	WO
0110319	Feb 2001	WO
0148153	Jul 2001	WO
2001048153	Jul 2001	WO
0170114	Sep 2001	WO
0181533	Nov 2001	WO
02078527	Oct 2002	WO
02089686	Nov 2002	WO
02100459	Dec 2002	WO
2003020144	Mar 2003	WO
2003047684	Jun 2003	WO
03099382	Dec 2003	WO
2004037341	May 2004	WO
2004080347	Sep 2004	WO
2005065284	Jul 2005	WO
2006017666	Feb 2006	WO
2006031541	Mar 2006	WO
2006130194	Dec 2006	WO
2007067628	Jun 2007	WO
2007067937	Jun 2007	WO
2007067938	Jun 2007	WO
2007067939	Jun 2007	WO
2007067940	Jun 2007	WO
2007067941	Jun 2007	WO
2007067943	Jun 2007	WO
2007070361	Jun 2007	WO
2007100727	Sep 2007	WO
2007123690	Nov 2007	WO
2008063195	May 2008	WO
2008034103	Nov 2008	WO
2009046176	Apr 2009	WO
2007137303	Jul 2009	WO
2009134876	Nov 2009	WO
2009135070	Nov 2009	WO
2009137800	Nov 2009	WO
2010064154	Jun 2010	WO
2010080974	Jul 2010	WO
2010117806	Oct 2010	WO
2010118387	Oct 2010	WO
2010132472	Nov 2010	WO
2010151277	Dec 2010	WO
2011047387	Apr 2011	WO
2011062653	May 2011	WO
2011072221	Jun 2011	WO
2012051433	Apr 2012	WO
2012071526	May 2012	WO
2012088149	Jun 2012	WO
2015175570	Nov 2015	WO
2016100325	Jun 2016	WO
2016164930	Oct 2016	WO

Non-Patent Literature Citations (371)

Entry
International Search Report for PCT/US2015/065792 dated Feb. 9, 2016.
Nuccitelli, R., et al., A new pulsed electric field therapy for melanoma disrupts the tumor's blood supply and causes complete remission without recurrence. Int J Cancer, 2009. 125(2): p. 438-45.
Davalos, R.V., L.M. Mir, and B. Rubinsky, Tissue Ablation with Irreversible Electroporation. Ann Biomed Eng, 2005. 33(2): p. 223-31.
Pavselj, N., V. Preat, and D. Miklavcic, A numerical model of skin electroporation as a method to enhance gene transfection in skin. 11th Mediterranean Conference on Medical and Biological Engineering and Computing 2007, vols. 1 and 2, 2007. 16(1-2): p. 597-601.
Pavselj, N., et al., The course of tissue permeabilization studied on a mathematical model of a subcutaneous tumor in small animals. Ieee Transactions on Biomedical Engineering, 2005. 52(8): p. 1373-1381.
Abidor, I.G., et al., Electric Breakdown of Bilayer Lipid-Membranes .1. Main Experimental Facts and Their Qualitative Discussion. Bioelectrochemistry and Bioenergetics, 1979. 6(1): p. 37-52.
Benz, R., F. Beckers, and U. Zimmermann, Reversible electrical breakdown of lipid bilayer membranes: a charge-pulse relaxation study. J Membr Bioi, 1979. 48(2): p. 181-204.
Neumann, E. and K. Rosenheck, Permeability changes induced by electric impulses in vesicular membranes. J Membr Bioi, 1972. 10(3): p. 279-90.
Teissie, J. and T.V. Tsang, Electric-Field Induced Transient Pores in Phospholipid-Bilayer Vesicles. Biochemistry, 1981. 20(6): p. 1548-1554.
Zimmermann, U., G. Pilwat, and F. Riemann, Dielectric breakdown of cell membranes. Biophys J, 1974. 14(11): p. 881-99.
Kinosita, K. and T.V. Tsang, Formation and Resealing of Pores of Controlled Sizes in Human Erythrocyte-Membrane. Nature, 1977. 268(5619): p. 438-441.
Davalos, R.V., et al., Electrical impedance tomography for imaging tissue electroporation. IEEE Trans Biomed Eng, 2004. 51(5): p. 761-767.
Ybarra, Gary A, et al. “Breast Imaging using Electrical Impedance Tomography.” in Suri, J.S., R.M. Rangayyan, and S. Laxminarayan, Emerging Technologies in Breast Imaging and Mammography2008: American Scientific Publishers.
Gabriel, C., Dielectric properties of biological tissue: variation with age. Bioelectromagnetics, 2005. Suppl 7: p. S12-8.
Song, Z.Q., et al., Mechanisms for steep pulse irreversible electroporation technology to kill human large cell lung cancer cells L9981. International Journal of Clinical and Experimental Medicine, 2014. 7(8): p. 2386-2394.
Garcia, P.A., R.V. Davalos, and D. Miklavcic, A Numerical Investigation of the Electric and Thermal Cell Kill Distributions in Electroporation-Based Therapies in Tissue. Plos One, 2014. 9(8).
Sel, D., et al., Sequential finite element model of tissue electropermeabilization. IEEE Trans Biomed Eng, 2005. 52(5): p. 816-27.
Neal, R.E., 2nd, et al., Experimental Characterization and Numerical Modeling of Tissue Electrical Conductivity during Pulsed Electric Fields for Irreversible Electroporation Treatment Planning. IEEE Trans. Biomed Eng, 2012. 59(4): p. 1076-85.
Garcia, P.A., et al., Intracranial Nonthermal Irreversible Electroporation: In Vivo Analysis. Journal of Membrane Biology, 2010. 236(1): p. 127-136.
Hjouj, Mohammad et al., “Electroporation-Induced BBB Disruption and Tissue Damage Depicted by MRI,” Abstracts From 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, Nov. 17-20, 2011, Orange County California, Neuro-Oncology Supplement, vol. 13, Supplement 3, p. ii114.
Ho, et al., Electroporation of Cell Membranes: A Review, Critical Reviews in Biotechnology, 16(4): 349-362, 1996.
Holder, et al., Assessment and Calibration of a Low-Frequency System for Electrical Impedance Tomography (EIT), Optimized for Use in Imaging Brain Function in Ambulant Human Subjects, Annals of the New York Academy of Science, vol. 873, Issue 1, Electrical Bl, pp. 512-519, 1999.
Huang, et al., Micro-Electroporation: Improving the Efficiency and Understanding of Electrical Permeabilization of Cells, Biomedical Microdevices, vol. 2, pp. 145-150, 1999.
Hughes, et al., An Analysis of Studies Comparing Electrical Impedance Tomography with X-Ray Videofluoroscopy in the Assessment of Swallowing, Physiol. Meas. 15, 1994, pp. A199-A209.
Ibey et al., “Selective cytotoxicity of intense nanosecond-duration electric pulses in mammalian cells.” Biochimica Et Biophysica Acta-General Subjects, vol. 1800, pp. 1210-1219 (2010).
Issa, et al., the TUNA Procedure for BPH: Review of the Technology: The TUNA Procedure for BPH: Basic Procedure and Clinical Results, Reprinted from Infections in Urology, Jul./Aug. 1998 and Sep./Oct. 1998.
Vanu{hacek over (s)}a, et al., MRI Macromolecular Contrast Agents as Indicators of Changed Tumor Blood Flow, Radiol. Oncol. 2001; 35(2): 139-47.
Vorra et al., “In vivo electric impedance measurements during and after electroporation of rat live.” Bioelectrochemistry, vol. 70, Pgs. 287-295 (2007).
Vorra et al., “In vivo electrical conductivity measurements during and after tumor electroporation: conductivity changes reflect the treatment outcome.” Physics in Medicine and Biology, vol. 54, Pgs. 5949-5963 (2009).
Vorra, “Bioimpedance monitoring for physicians: an overview.” Biomedical Applications Group, 35 pages (2002).
Jarm et al., “Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases.” Expert Rev Anticancer Ther. vol. 10, pp. 729-746 (2010).
Jaroszeski, et al., In Vivo Gene Delivery by Electroporation, Advanced Drug Delivery Review, vol. 35, pp. 131-137, 1999.
Jensen et al., “Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18FFDG-microPET or external caliper.” BMC medical Imaging vol. 8:16, 9 Pages (2008).
Jossinet et al., Electrical Impedance Endo-Tomography: Imaging Tissue From Inside, IEEE Transactions on Medical Imaging, Vol. 21, No. 6, Jun. 2002, pp. 560-565.
Kingham et al., “Ablation of perivascular hepatic malignant tumors with irreversible electroporation.” Journal of the American College of Surgeons, 2012. 215(3), p. 379-387.
Kinosita and Tsong, “Formation and resealing of pores of controlled sizes in human erythrocyte membrane.” Nature, vol. 268 (1977) pp. 438-441.
Kinosita and Tsong, “Voltage-induced pore formation and hemolysis of human erythrocytes.” Biochimica et Biophysica Acta (BBA)-Biomembranes, 471 (1977) pp. 227-242.
Kinosita et al.' “Electroporation of cell membrane visualized under a pulsed-laser fluorescence microscope.” Biophysical Journal, vol. 53, pp. 1015-1019 (1988).
Kinosita, et al., Hemolysis of Human Erythrocytes by a Transient Electric Field, Proc. Natl. Acad. Sci. USA, vol. 74, No. 5, pp. 1923-1927, 1977.
Kirson et al., “Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.” Proceedings of the National Academy of Sciences vol. 104, pp. 10152-10157 (2007).
Kotnik and Miklavcic, “Theoretical evaluation of voltage inducement on internal membranes of biological cells exposed to electric fields.” Biophysical Journal, vol. 90(2), pp. 480-491 (2006).
Kotnik et al., “Sensitivity of transmembrane voltage induced by applied electric fields—A theoretical analysis”, Bioelectrochemistry and Bioenergetics,vol. 43, Issue 2, 1997, pp. 285-291.
Kotnik, T. And D. Miklavcic, “Theoretical evaluation of the distributed power dissipation in biological cells exposed to electric fields”, Bioelectromagnetics, 21(5): p. 385-394 (2000).
Kotnik, T., et al., “Cell membrane electropermeabilization by symmetrical bipolar rectangular pulses. Part II. Reduced electrolytic contamination”, Bioelectrochemistry, 54(1): p. 91-5 (2001).
Kotnik, T., et al., “Role of pulse shape in cell membrane electropermeabilization”, Biochimica Et Biophysica Acta-Biomembranes, 1614(2): p. 193-200 (2003).
Labeed et al., “Differences in the biophysical properties of membrane and cytoplasm of apoptotic cells revealed using dielectrophoresis.” Biochimica et Biophysica Acta (BBA)-General Subjects, vol. 1760, pp. 922-929 (2006).
Lackovic, I., et al., “Three-dimensional Finite-element Analysis of Joule Heating in Electrochemotherapy and in vivo Gene Electrotransfer”, leee Transactions on Dielectrics and Electrical Insulation, 16(5): p. 1338-1347 (2009).
Laufer et al., “Electrical impedance characterization of normal and cancerous human hepatic tissue.” Physiological Measurement, vol. 31, Pp. 995-1009 (2010).
Lebar et al., “Inter-pulse interval between rectangular voltage pulses affects electroporation threshold of artificial lipid bilayers.” IEEE Transactions on NanoBioscience, vol. 1 (2002) pp. 116-120.
Lee E. W. et al. Advanced Hepatic Ablation Technique for Creating Complete Cell Death: Irreversible Electroporation. Radiology 255, 426-433, doi:10.1148/radiol.10090337 (2010).
Lee, E.W., et al., “Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation”, Technol Cancer Res Treat 6: 287-294 (2007).
Li, W., et al., “The Effects of Irreversible Electroporation (IRE) on Nerves” PloS One, Apr. 2011, 6(4), e18831.
Liu, et al. Measurement of Pharyngeal Transit Time by Electrical Impedance Tomography, Clin. Phys. Physiol. Meas., 1992, vol. 13, Suppl. A, pp. 197-200.
et al., “Targeted Tissue Ablation With Nanosecond Pulses”. leee Transactions on Biomedical Engineering, 58(8) (2011).
Lundqvist et al. Altering the Biochemical State of Individual Cultured Cells and Organelles with Ultramicroelectrodes, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 10356-10360, Sep. 1998.
Lurquin, Gene Transfer by Electroporation, Molecular Biotechnology, vol. 7, 1997.
Lynn et al., A New Method for the Generation and Use of Focused Ultrasound in Experimental Biology, The Journal Df General Physiology, vol. 26, 179-193, 1942.
Ma{hacek over (c)}ek Lebar and Miklav{hacek over (c)}id, “Cell electropermeabilization to small molecules in vitro: control by pulse parameters.” Radiology and Oncology, vol. 35(3), pp. 193-202 (2001).
Mahmood, F., et al., “Diffusion-Weighted MRI for Verification of Electroporation-Based Treatments”, Journal of Membrane Biology 240: 131-138 (2011).
Mahnic-Kalamiza, S., et al., “Educational application for visualization and analysis of electric field strength in multiple electrode electroporation,” BMC Med Educ, vol. 12, p. 102, 2012.
Malpica et al., “Grading ovarian serous carcinoma using a two-tier system.” The American Journal of Surgical Pathology, vol. 28, pp. 496-504 (2004).
Maor et al., The Effect of Irreversible Electroporation on Blood Vessels, Tech. In Cancer Res. And Treatment, vol. 6, No. 4, Aug. 2007, pp. 307-312.
Vlaor, E., a Ivorra, and B. Rubinsky, Non Thermal Irreversible Electroporation: Novel Technology for Vascular Smooth Vluscle Cells Ablation, PLoS One, 2009, 4(3): p. e4757.
Maor, E., A Ivorra, J. Leor, and B. Rubinsky, Irreversible electroporation attenuates neointimal formation after angioplasty, IEEE Trans Biomed Eng, Sep. 2008, 55(9): p. 2268-74.
Marszalek et al., “Schwan equation and transmembrane potential induced by alternating electric field.” Biophysical Journal, vol. 58, pp. 1053-1058 (1990).
Martin, n. R.C.G., et al., “Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma” Journal of the American College of Surgeons, 2012. 215(3): p. 361-369.
Marty, M., et al., “Electrochemotherapy — An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study,” European Journal of Cancer Supplements, 4, 3-13, 2006.
Miklav{hacek over (c)}i{hacek over (c)}, et al., A Validated Model of an in Vivo Electric Field Distribution in Tissues for Electrochemotherapy and for DNA Electrotransfer for Gene Therapy, Biochimica et Biophysica Acta 1523 (2000), pp. 73-83.
Miklav{hacek over (c)}i{hacek over (c)}, et al., the Importance of Electric Field Distribution for Effective in Vivo Electroporation of Tissues, Biophysical Journal, vol. 74, May 1998, pp. 2152-2158.
Co-pending U.S. Appl. No. 13/550,307 Non-final office action dated Aug. 22, 2019, 19 pages.
Co-pending U.S. Appl. No. 13/550,307 Notice of panel decision from pre-appeal brief review dated May 16, 2019, 2 pages.
Co-pending U.S. Appl. No. 13/550,307 Pre-appeal brief request for review dated Apr. 4, 2019, 7 pages.
Co-Pending U.S. Appl. No. 14/558,631, Final Office Action dated Sep. 1, 2017, 9 pages.
Co-Pending U.S. Appl. No. 14/558,631, Non-Final Office Action dated Jan. 8, 2018, 5 pages.
Co-Pending U.S. Appl. No. 14/558,631, Non-Final Office Action dated Mar. 13, 2017, 10 pages.
Co-Pending U.S. Appl. No. 14/558,631, Notice of Allowance dated Jul. 17, 2018, 2 pages.
Co-Pending U.S. Appl. No. 14/558,631, Notice of Allowance dated Jun. 21, 2018, 7 pages.
Co-Pending U.S. Appl. No. 14/558,631, Response to Jan. 8, 2018 Non-Final Office Action dated Apr. 9, 2018, 8 pages.
Co-Pending U.S. Appl. No. 14/558,631, Response to Mar. 13, 2017 Non-Final Office Action dated Jul. 13, 2017, 10 pages.
Co-Pending U.S. Appl. No. 14/558,631, Response to Sep. 1, 2017 Final Office Action dated Dec. 1, 2017, 7 pages.
Co-Pending U.S. Appl. No. 14/558,631, filed Dec. 2, 2014.
Co-Pending Application U.S. Appl. No. 14/686,380, filed Apr. 14, 2015 and Published as U.S. 2015/0289923 dated Oct. 15, 2015.
Co-Pending Application U.S. Appl. No. 14/808,679, filed Jul. 24, 2015 and Published as U.S. Publication No. 2015/0327944 dated Nov. 19, 2015.
Co-Pending U.S. Appl. No. 14/940,863, Notice of Allowance dated Jan. 25, 2019, 5 pages.
Co-Pending U.S. Appl. No. 14/940,863, Notice of Allowance dated Sep. 19, 2018, 9 pages.
Co-Pending U.S. Appl. No. 14/940,863, Notice of Allowance dated Sep. 19, 2018, 5 pages.
Co-pending U.S. Appl. No. 15/011,752 Final Office Action dated Dec. 19, 2018, 6 pages.
Co-pending U.S. Appl. No. 15/011,752 Non-Final Office Action dated May 11, 2018, 11 pages.
Co-pending U.S. Appl. No. 15/011,752 Notice of Allowance dated Mar. 22, 2019, 6 pages.
Co-pending U.S. Appl. No. 15/011,752 Preliminary Amendment, filed Feb. 2, 2016, 6 pages.
Co-pending U.S. Appl. No. 15/011,752 Response to Dec. 19, 2018 Final Office Action, filed Mar. 5, 2019, 6 pages.
Co-pending U.S. Appl. No. 15/011,752 Response to May 11, 2018 Non-Final Office Action dated Oct. 11, 2018, 11 pages.
Co-pending U.S. Appl. No. 15/011,752, filed Feb. 1, 2016.
Co-pending U.S. Appl. No. 15/186,653, filed Jun. 20, 2016.
Co-Pending U.S. Appl. No. 15/310,114, filed Nov. 10, 2016.
Co-pending U.S. Appl. No.15/423,986, filed Feb. 3, 2017.
Co-pending U.S. Appl. No.15/424,335, filed Feb. 3, 2017.
Co-pending U.S. Appl. No. 15/843,888, filed Dec. 15, 2017.
Co-pending U.S. Appl. No. 15/881,414, filed Jan. 26, 2018.
Co-pending U.S. Appl. No. 16/152,743 Preliminary Amendment filed Oct. 5, 2018, 7 pages.
Co-pending U.S. Appl. No. 16/177,745, filed Nov. 1, 2018.
Co-pending U.S. Appl. No. 16/232,962, filed Dec. 26, 2018.
Co-pending U.S. Appl. No. 16/275,429, filed Feb. 14, 2019, which published as 2019/0175260 dated Jun. 13, 2019.
Co-pending U.S. Appl. No. 16/275,429 Preliminary Amendment Filed Mar. 28, 2019, 6 pages.
Co-pending U.S. Appl. No. 16/280,511, filed Feb. 20, 2019.
Co-pending U.S. Appl. No. 16/372,520, filed Apr. 2, 2019, which published as 20190223938 on Jul. 25, 2019.
Co-Pending U.S. Appl. No. 16/375,878, filed Apr. 5, 2019, which published dated Aug. 1, 2019 as US 2019-0233809 A1.
Co-pending U.S. Appl. No. 16/404,392, filed May 6, 2019.
Co-pending U.S. Appl. No 16/443,351, filed Jun. 17, 2019 (published as 20190328445 dated Oct. 31, 2019).
Co-pending U.S. Appl. No. 16/520,901, filed Jul. 24, 2019.
Co-pending U.S. Appl. No. 16/535,451, filed Aug. 8, 2019.
Co-Pending U.S. Appl. No. 16/655,845, filed Oct. 17, 2019.
Co-Pending U.S. Appl. No. PCT/US04/43477, filed Dec. 21, 2004.
Co-Pending Application No. PCT/US09/42100, filed Apr. 29, 2009.
Coo-Pending Application No. PCT/US09/62806, filed Oct. 30, 2009.
Co-Pending Application No. PCT/US10/30629, filed Apr. 9, 2010.
Co-Pending Application No. PCT/US10/53077, filed Oct. 18, 2010.
Co-Pending Application No. PCT/US11/62067, filed Nov. 23, 2011.
Co-Pending Application No. PCT/US11/66239, filed Dec. 20, 2011.
Zimmermann, et al., Dielectric Breakdown of Cell Membranes, Biophysical Journal, vol. 14, No. 11, pp. 881-899, 1974.
Zlotta, et al., Long-Term Evaluation of Transurethral Needle Ablation of the Prostate (TUNA) for Treatment of Benign Prostatic Hyperplasia (BPH): Clinical Outcome After 5 Years. (Abstract) Presented at 2001 AUA National Meeting, Anaheim, CA-Jun. 5, 2001.
Zlotta, et al., Possible Mechanisms of Action of Transurethral Needle Ablation of the Prostate on Benign Prostatic Hyperplasia Symptoms: a Neurohistochemical Study, Reprinted from Journal of Urology, vol. 157, No. 3, Mar. 1997, pp. 894-899.
Agerholm-Larsen, B., et al., “Preclinical Validation of Electrochemotherapy as an Effective Treatment for Brain Tumors”, Cancer Research 71: 3753-3762 (2011).
Alberts et al., “Molecular Biology of the Cell,” 3rd edition, Garland Science, New York, 1994, 1 page.
Al-Sakere, B. et al., 2007, “Tumor ablation with irreversible electroporation.” PLoS One 2.
Amasha, et al., Quantitative Assessment of Impedance Tomography for Temperature Measurements in Microwave Hyperthermia, Clin. Phys. Physiol. Meas., 1998, Suppl. A, 49-53.
Andreason, Electroporation as a Technique for the Transfer of Macromolecules into Mammalian Cell Lines, J. Tiss. Cult. Meth., 15:56-62, 1993.
Appelbaum, L., et al., “U.S. Findings after Irreversible Electroporation Ablation: Radiologic-Pathologic Correlation” Radiology 262(1), 117-125 (2012).
Arena et al. “High-Frequency Irreversible Electroporation (H-FIRE) for Non-thermal Ablation without Muscle contraction.” Biomed. Eng. Online, vol. 10, 20 pages. (2011).
Arena, C.B., et al., “A three-dimensional in vitro tumor platform for modeling therapeutic irreversible electroporation.” Biophysical Journal, 2012103(9): p. 2033-2042.
Arena, Christopher B., et al., “Towards the development of latent heat storage electrodes for electroporation-based therapies”, Applied Physics Letters, 101, 083902 (2012).
Arena, Christopher B., et al.,“Phase Change Electrodes for Reducing Joule Heating During Irreversible Electroporation”. Proceedings of the ASME 2012 Summer Bioengineering Conference, SBC2012, Jun. 20-23, 2012, Fajardo, Puerto Rico.
Asami et al., “Dielectric properties of mouse lymphocytes and erythrocytes.” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1010 (1989) pp. 49-55.
Bagla, S. And Papadouris, D., “Percutaneous Irreversible Electroporation of Surgically Unresectable Pancreatic cancer: A Case Report” J. Vascular Int. Radio. 23(1), 142-145 (2012).
Baker, et al., Calcium-Dependent Exocytosis in Bovine Adrenal Medullary Cells with Leaky Plasma Membranes, Nature, vol. 276, pp. 620-622, 1978.
Ball, C., K.R. Thomson, and H. Kavnoudias, “Irreversible electroporation: a new challenge in ”out of-operating theater“ anesthesia.” Anesth Analg, 2010. 110(5): p. 1305-9.
Bancroft, et al., Design of a Flow Perfusion Bioreactor System for Bone Tissue-Engineering Applications, Tissue Engineering, vol. 9, No. 3, 2003, p. 549-554.
Baptista et al., “The Use of Whole Organ Decellularization for the Generation of a Vascularized Liver Organoid,” Heptatology, vol. 53, No. 2, pp. 604-617 (2011).
Barber, Electrical Impedance Tomography Applied Potential Tomography, Advances in Biomedical Engineering, Beneken and Thevenin, eds., IOS Press, pp. 165-173, 1993.
Beebe, S.J., et al., “Diverse effects of nanosecond pulsed electric fields on cells and tissues”, DNA and Cell Biology, 22(12): 785-796 (2003).
Beebe, S.J., et al., Nanosecond pulsed electric field (nsPEF) effects on cells and tissues: apoptosis induction and tumor growth inhibition. PPPS-2001 Pulsed Power Plasma Science 2001, 28th IEEE International Conference on PIasma Science and 13th IEEE International Pulsed Power Conference, Digest of Technical Papers (Cat. No. 01CH37251). IEEE, Part vol. 1, 2001, pp. 211-15, vol. I, Piscataway, NJ, USA.
Ben-David, E.,et al., “Characterization of Irreversible Electroporation Ablation in In Vivo Procine Liver” Am. J. Roentgenol. 198(1), W62-W68 (2012).
Blad, et al.' Impedance Spectra of Tumour Tissue in Comparison with Normal Tissue; a Possible Clinical Application for Electrical Impedance Tomography, Physiol. Meas. 17 (1996) A105-A115.
Bolland, F., et al., “Development and characterisation of a full-thickness acellular porcine bladder matrix for tissue engineering”, Biomaterials, Elsevier Science Publishers, Barking, GB, vol. 28, No. 6, 28 Nov. 2006, pp. 1061-1070.
Boone, K., Barber, D. & Brown, B. Review—Imaging with electricity: report of the European Concerted Action on impedance Tomography J. Med. Eng. Technol. 21, 201-232 (1997).
Bower et al., “Irreversible electroporation of the pancreas: definitive local therapy without systemic effects.” Journal of surgical oncology, 2011. 104(1): p. 22-28.
BPH Management Strategies: Improving Patient Satisfaction, Urology Times, May 2001, vol. 29, Supplement 1.
Brown, et al., Blood Flow Imaging Using Electrical Impedance Tomography, Clin. Phys. Physiol. Meas., 1992, vol. 13, Suppl. A, 175-179.
Brown, S.G., Phototherapy of tumors. World J. Surgery, 1983. 7: p. 700-9.
Cannon et al., “Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures.” Journal of Surgical Oncology, 6 pages. (2012).
Carpenter A.E. et al., “CellProfiler: image analysis software for identifying and quantifying cell phenotypes.” Genome Biol. 2006; 7(10): R100. Published online Oct. 31, 2006, 11 pages.
Cemazar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM, et al., “Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy”, Br J Cancer 84: 565-570 (2001).
Chandrasekar, et al., Transurethral Needle Ablation of the Prostate (TUNA) —a Propsective Study, Six Year Follow Up, (Abstract), Presented at 2001 National Meeting, Anaheim, CA, Jun. 5, 2001.
Chang, D.C., “Cell Poration and Cell-Fusion Using an Oscillating Electric-Field”. Biophysical Journal, 56(4): p. 541-652 (1989).
Charpentier, K.P., et al., “Irreversible electroporation of the pancreas in swine: a pilot study.” HPB: the official journal of the International Hepato Pancreato Biliary Association, 2010. 12(5): p. 348-351.
Chen et al., “Classification of cell types using a microfluidic device for mechanical and electrical measurement on single cells.” Lab on a Chip, vol. 11, pp. 3174-3181 (2011).
Chen, M.T. et al. “Two-dimensional nanosecond electric field mapping based on cell electropermeabilization”, PMC Biophys, 2(1):9 (2009).
Clark et al., “The electrical properties of resting and secreting pancreas.” The Journal of Physiology, vol. 189, pp. 247-260 (1967).
Coates, C.W.,et al., “The Electrical Discharge of the Electric Eel, Electrophorous Electricus,” Zoologica, 1937, 22(1), pp. 1-32.
Cook, et al., ACT3: A High-Speed, High-Precision Electrical Impedance Tomgraph, IEEE Transactions on Biomedical Engineering, vol. 41, No. 8, Aug. 1994.
Co-Pending U.S. Appl. No. 12/432,295, filed Apr. 29, 2009.
Co-pending U.S. Appl. No. 10/571,162 filed Oct. 18, 2006 (published as 2007/0043345 dated Feb. 22, 2007).
Co-Pending U.S. Appl. No. 12/609,779, filed Oct. 30, 2009.
Co-pending U.S. Appl. No. 12/751,826, filed Mar. 31, 2010 (published as 2010/0250209 dated Sep. 30, 2010).
Co-pending U.S. Appl. No. 12/751,854, filed Mar. 31, 2010 (published as 2010/0249771 dated Sep. 30, 2010).
Co-Pending U.S. Appl. No. 12/757,901, filed Apr. 9, 2010.
Co-Pending U.S. Appl. No. 12/757,901, Issued as U.S. Pat. No. 8,926,606 dated Jan. 6, 2015, 42 pages.
Co-Pending U.S. Appl. No. 12/906,923, Office Actions and Responses dated Jul. 2017, 55 pages.
Co-Pending U.S. Appl. No. 12/906,923, filed Oct. 18, 2010.
Co-Pending U.S. Appl. No. 12/906,923, Non-Final Office Action dated Oct. 24, 2014, 11 pages.
Co-Pending U.S. Appl. No. 12/906,923, Requirement for Restriction/Election, dated Jan. 29, 2014, 9 pages.
Co-Pending U.S. Appl. No. 12/906,923, Response to Restriction Requirement, dated Mar. 19, 2014, 3 pages.
Miller, L, et al., Cancer cells ablation with irreversible electroporation, Technology in Cancer Research and Treatment 4 (2005) 699-706.
Mir et al., “Mechanisms of Electrochemotherapy” Advanced Drug Delivery Reviews 35:107-118 (1999).
Mir, et al., Effective Treatment of Cutaneous and Subcutaneous Malignant Tumours by Electrochemotherapy, British Journal of Cancer, vol. 77, No. 12, pp. 2336-2342, 1998.
Mir, et al., Electrochemotherapy Potentiation of Antitumour Effect of Bleomycin by Local Electric Pulses, European Journal of Cancer, vol. 27, No. 1, pp. 68-72, 1991.
Mir, et al., Electrochemotherapy, a Novel Antitumor Treatment: First Clinical Trial, C.R. Acad. Sci. Paris, Ser. III, vol. 313, pp. 613-618, 1991.
Mir, L.M. and Orlowski, S., The basis of electrochemotherapy, in Electrochemotherapy, electrogenetherapy, and transdermal drug delivery: electrically mediated delivery of molecules to cells, M.J. Jaroszeski, R. Heller, R. Gilbert, Editors, 2000, Humana Press, p. 99-118.
Mir, L.M., et al., Electric Pulse-Mediated Gene Delivery to Various Animal Tissues, in Advances in Genetics, Academic Press, 2005, p. 83-114.
Mir, Therapeutic Perspectives of in Vivo Cell Electropermeabilization, Bioelectrochemistry, vol. 53, pp. 1-10, 2000.
Mulhall et al., “Cancer, pre-cancer and normal oral cells distinguished by dielectrophoresis.” Analytical and Bioanalytical Chemistry, vol. 401, pp. 2455-2463 (2011).
Narayan, et al., Establishment and Characterization of a Human Primary Prostatic Adenocarcinoma Cell Line (ND-1), The Journal of Urology, vol. 148, 1600-1604, Nov. 1992.
Naslund, Cost-Effectiveness of Minimally Invasive Treatments and Transurethral Resection (TURP) in Benign Prostatic Hyperplasia (BPH), (Abstract), Presented at 2001 AUA National Meeting Anaheim, CA, Jun. 5, 2001.
Naslund, Michael J., Transurethral Needle Ablation of the Prostate, Urology, vol. 50, No. 2, Aug. 1997.
Neal II et al., “A Case Report on the Successful Treatment of a Large Soft-Tissue Sarcoma with Irreversible Electroporation,” Journal of Clinical Oncology, 29, pgs. 1-6, 2011.
Neal II, R. E., et al., “Experimental characterization and numerical modeling of tissue electrical conductivity during Dulsed electric fields for irreversible electroporation treatment planning,” IEEE Trans Biomed Eng., vol. 59:4, pp. 1076-85. Epub Jan. 6, 2012.
Neal II, R. E., et al., “Successful Treatment of a Large Soft Tissue Sarcoma with Irreversible Electroporation”, Journal of Clinical Oncology, 29:13, e372-e377 (2011).
Neal II, R.E. et al., “Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode.” Breast Cancer Research and Treatment, 2010. 123(1): p. 295-301.
Neal II, Robert E. and R.V. Davalos, The Feasibility of Irreversible Electroporation for the Treatment of Breast Cancer and Other Heterogeneous Systems, Ann Biomed Eng, 2009, 37(12): p. 2615-2625.
Neal Re II, et al. (2013) Improved Local and Systemic Anti-Tumor Efficacy for Irreversible Electroporation in Immunocompetent versus Immunodeficient Mice. PLoS One 8(5): e64559. https://doi.org/10.1371/journal.bone.0064559.
Nesin et al., “Manipulation of cell volume and membrane pore comparison following single cell permeabilization with 60- and 600-ns electric pulses.” Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1808, pp. 792-801(2011).
Neumann, et al., Gene Transfer into Mouse Lyoma Cells by Electroporation in High Electric Fields, J. Embo., vol. 1, No. 7, pp. 841-845, 1982.
Neumann, et al., Permeability Changes Induced by Electric Impulses in Vesicular Membranes, J. Membrane Biol., vol. 10, pp. 279-290, 1972.
Nikolova, B., et al., “Treatment of Melanoma by Electroporation of Bacillus Calmette-Guerin”. Biotechnology & Biotechnological Equipment, 25(3): p. 2522-2524 (2011).
Nuccitelli, R., et al., “A new pulsed electric field therapy for melanoma disrupts the tumor's blood supply and causes complete remission without recurrence”, Int J Cancer, 125(2): p. 438-45 (2009).
O'Brien et al., “Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.” European Journal of Biochemistry, vol. 267, pp. 5421-5426 (2000).
Okino, et al., Effects of High-Voltage Electrical Impulse and an Anticancer Drug on in Vivo Growing Tumors, Japanese Journal of Cancer Research, vol. 78, pp. 1319-1321, 1987.
Onik, et al., Sonographic Monitoring of Hepatic Cryosurgery in an Experimental Animal Model, AJR American J. Of Roentgenology, vol. 144, pp. 1043-1047, May 1985.
Onik, et al., Ultrasonic Characteristics of Frozen Liver, Cryobiology, vol. 21, pp. 321-328, 1984.
Onik, G. And B. Rubinsky, eds. “Irreversible electroporation: first patient experience focal therapy of prostate Cancer. Irreversible Electroporation”, ed. B. Rubinsky 2010, Springer Berlin Heidelberg, pgs. 235-247.
Onik, G., P. Mikus, and B. Rubinsky, “Irreversible electroporation: implications for prostate ablation.” Technol Cancer Res Treat, 2007. 6(4): p. 295-300.
Organ, L.W., Electrophysiological principles of radiofrequency lesion making, Apply. Neurophysiol., 1976. 39: p. 69-76.
Ott, H. C., et al., “Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart”, Nature Medicine, Nature Publishing Group, New York, NY, US, vol. 14, No. 2, Feb. 1, 2008, pp. 213-221.
Paszek et al., “Tensional homeostasis and the malignant phenotype.” Cancer Cell, vol. 8, pp. 241-254 (2005).
Payselj, N. et al. The course of tissue permeabilization studied on a mathematical model of a subcutaneous tumor in small animals. IEEE Trans Biomed Eng 52, 1373-1381 (2005).
PCT International Preliminary Report on Patentability of Corresponding International Application No. PCT/2011/062067, dated May 28, 2013.
PCT International Preliminary Report on Patentability of Corresponding International Application No. PCT/2011/066239, dated Jun. 25, 2013.
PCT International Search Report dated (Aug. 2, 2011), Written Opinion dated (Aug. 2, 2011), and International Preliminary Report on Patentability dated (Apr. 17, 2012) of PCT/US10/53077.
PCT International Search Report dated (Aug. 22, 2012), and Written Opinion dated (Aug. 22, 2012) of PCT/US11/66239.
PCT International Search Report dated (Aug. 26, 2005), Written Opinion dated (Aug. 26, 2005), and International Preliminary Report on Patentability dated (Jun. 26, 2006) of PCT/US2004/043477.
PCT International Search Report dated (Jan. 19, 2010), Written Opinion dated (Jan. 19, 2010), and International Preliminary Report on Patentability dated (Jan. 4, 2010) of PCT/US09/62806, 15 pgs.
PCT International Search Report dated (Jul. 15, 2010), Written Opinion dated (Jul. 15, 2010), and International Preliminary Report on Patentability dated (Oct. 11, 2011) from PCT/US2010/030629.
PCT International Search Report (Jul. 9, 2009), Written Opinion dated (Jul. 9, 2009), and International Preliminary Report on Patentability dated (Nov. 2, 2010) of PCT/US2009/042100.
PCT International Search Report and Written Opinion dated (Jul. 25, 2012) of PCT/US2011/062067.
PCT International Search Report, 4 pgs, dated (Jul. 30, 2010), Written Opinion, 7 pgs, dated (Jul. 30, 2010), and International Preliminary Report on Patentability, 8 pgs, dated (Oct. 4, 2011) from PCT/US2010/029243.
PCT IPRP for PCTIUSI5/30429 (WO2015175570), dated Nov. 15, 2016.
Phillips, M., Maor, E. & Rubinsky, B. Non-Thermal Irreversible Electroporation for Tissue Decellularization. J. Biomech. Eng, doi:10.1115/1.4001882 (2010).
Piñero, et al., Apoptotic and Necrotic Cell Death Are Both Induced by Electroporation in HL60 Human Promyeloid Leukaemia Cells, Apoptosis, vol., 2, No. 3, 330-336, Aug. 1997.
Polak et al., “On the Electroporation Thresholds of Lipid Bilayers: Molecular Dynamics Simulation Investigations.” The Journal of Membrane Biology, vol. 246, pp. 843-850 (2013).
Precision Office TUNA System, When Patient Satisfaction is Your Goal, VidaMed 2001.
Pucihar et al., “Numerical determination of transmembrane voltage induced on irregularly shaped cells.” Annals of Biomedical Engineering, vol. 34, pp. 642-652 (2006).
Rajagopal, V. and S.G. Rockson, Coronary restenosis: a review of mechanisms and management, The American Journal of Medicine, 2003, 115(7): p. 547-553.
Dev, et al., Sustained Local Delivery of Heparin to the Rabbit Arterial Wall with an Electroporation Catheter, Catheterization and Cardiovascular Diagnosis, Nov., 1998, vol. 45, No. 3, pp. 337-343.
Duraiswami, et al., Boundary Element Techniques for Efficient 2-D and 3-D Electrical Impedance Tomography, Chemical Engineering Science, vol. 52, No. 13, pp. 2185-2196, 1997.
Duraiswami, et al., Efficient 2D and 3D Electrical Impedance Tomography Using Dual Reciprocity Boundary Element Techniques, Engineering Analysis with Boundary Elements 22, (1998) 13-31.
Duraiswami, et al., Solution of Electrical Impedance Tomography Equations Using Boundary Element Methods, Boundary Element Technology XII, 1997, pp. 226-237.
Edd, J., et al., In-Vivo Results of a New Focal Tissue Ablation Technique: Irreversible Electroporaton, IEEE Trans. Biomed. Eng. 53 (2006) p. 1409-1415.
Edd, J.F, et al., 2007, “Mathematical modeling of irreversible electroporation fortreatment planning.”, Technology in Cancer Research and Treatment, 6:275-286.
Ellis TL, Garcia PA, Rossmeisl JH, Jr., Henao-Guerrero N, Robertson J, et al., “Nonthermal irreversible electroporation for intracranial surgical applications. Laboratory investigation”, J Neurosurg 114: 681-688 (2011).
Eppich et al., “Pulsed electric fields for selection of hematopoietic cells and depletion of tumor cell contaminants.” Nature Biotechnology 18, pp. 882-887 (2000).
Erez, et al, Controlled Destruction and Temperature Distributions in Biological Tissues Subjected to Monoactive Electrocoagulation, Transactions of the ASME: Journal of Mechanical Design, vol. 102, Feb. 1980.
Ermolina et al., “Study of normal and malignant white blood cells by time domain dielectric spectroscopy.” IEEE Transactions on Dielectrics and Electrical Insulation, 8 (2001) pp. 253-261.
Esser, A.T., et al', “Towards solid tumor treatment by irreversible electroporation: intrinsic redistribution of fields and currents in tissue”. Technol Cancer Res Treat, 6(4): p. 261-74 (2007).
Esser, A.T., et al., “Towards Solid Tumor Treatment by Nanosecond Pulsed Electric Fields”. Technology in Cancer Research & Treatment, 8(4): p. 289-306 (2009).
Extended European Search Report. May 11, 2012. PCT/US2009042100 from EP 09739678.2.
Faroja, M., et al., “Irreversible Electroporation Ablation: Is the entire Damage Nonthermal?”, Radiology, 266(2), 462-470 (2013).
=Fischbach et al., “Engineering tumors with 3D scaffolds.” Nat Meth 4, pp. 855-860 (2007).
Flanagan et al., “Unique dielectric properties distinguish stem cells and their differentiated progeny.” Stem Cells, vol. 26, pp. 656-665 (2008).
Fong et al., “Modeling Ewing sarcoma tumors in vitro with 3D scaffolds.” Proceedings of the National Academy of Sciences vol. 110, pp. 6500-6505 (2013).
Foster RS, “High-intensity focused ultrasound in the treatment of prostatic disease”, European Urology, 1993, vol. 23 Suppl 1, pp. 29-33.
Foster, R.S., et al., Production of Prostatic Lesions in Canines Using Transrectally Administered High-Intensity Focused Ultrasound. Eur. Urol., 1993; 23: 330-336.
Fox, et al., Sampling Conductivity Images via MCMC, Mathematics Department, Auckland University, New Zealand, May 1997.
Freeman, S.A., et al., Theory of Electroporation of Planar Bilayer-Membranes—Predictions of the Aqueous Area, Change in Capacitance, and Pore-Pore Separation. Biophysical Journal, 67(1): p. 42-56 (1994).
Garcia et al., “Irreversible electroporation (IRE) to treat brain cancer.” ASME Summer Bioengineering Conference, Marco Island, FL, Jun. 25-29, 2008.
Garcia P.A., et al., “7.0-T Magnetic Resonance Imaging Characterization of Acute Blood-Brain-Barrier Disruption Achieved with Intracranial Irreversible Electroporation”, PLOS One, Nov. 2012, 7:11, e50482.
Garcia Pa., et al., “Pilot study of irreversible electroporation for intracranial surgery”, Conf Proc IEEE Eng Med Biol Soc, 2009:6513-6516, 2009.
Garcia PA, Rossmeisl JH, Jr., Neal RE, 2nd, Ellis TL, Davalos RV, “A Parametric Study Delineating Irreversible Electroporation from Thermal Damage Based on a Minimally Invasive Intracranial Procedure”, Biomed Eng Online 10: 34 (2011).
Garcia, P. A., et al., “Towards a predictive model of electroporation-based therapies using pre-pulse electrical measurements,” Conf Proc IEEE Eng Med Biol Soc, vol. 1 2012, pp. 2575-8, 2012.
Garcia, P. A., et al., “Non-thermal Irreversible Electroporation (N-TIRE) and Adjuvant Fractioned Radiotherapeutic Vlultimodal Therapy for Intracranial Malignant Glioma in a Canine Patient” Technol. Cancer Res. Treatment 10(1), 7333 (2011).
Garcia, P. et al. Intracranial nonthermal irreversible electroporation: in vivo analysis. J Membr Biol 236, 127-136 :2010).
Garcia, Paulo A., Robert E. Neal II and Rafael V. Davalos, Chapter 3, Non-Thermal Irreversible Electroporation for Tissue Ablation, in: Electroporation in Laboratory and Clinical Investigations ISBN 378-1-61668-327-6 Editors: Enrico P. Spugnini and Alfonso Baldi, 2010, 22 pp.
Gascoyne et al., “Membrane changes accompanying the induced differentiation of Friend murine erythroleukemia cells studied by dielectrophoresis.” Biochimica et Biophysica Acta (BBA)-Biomembranes, vol. 1149, pp. 119-126 (1993).
Gauger, et al., a Study of Dielectric Membrane Breakdown in the Fucus Egg, J. Membrane Biol., vol. 48, No. 3, pp. 249-264, 1979.
Gehl, et al.' in Vivo Electroporation of Skeletal Muscle: Threshold, Efficacy and Relation to Electric Field Distribution, . Thochimica et Biphysica Acta 1428, 1999, pp. 233-240.
Gençer, et al., Electrical Impedance Tomography: Induced-Current Imaging Achieved with a Multiple Coil System, Eee Transactions on Biomedical Engineering, vol. 43, No. 2, Feb. 1996.
Gilbert, et al., Novel Electrode Designs for Electrochemotherapy, Biochimica et Biophysica Acta 1334, 1997, pp. 9-14.
Gilbert, et al., the Use of Ultrasound Imaging for Monitoring Cryosurgery, Proceedings fith Annual Conference, IEEE Engineering in Medicine and Biology, 107-111, 1984.
Gilbert, T. W., et al., “Decellularization of tissues and organs”, Biomaterials, Elsevier Science Publishers, Barking, GB, vol. 27, No. 19, 1 Jul. 2006, pp. 3675-3683.
Gimsa et al., “Dielectric spectroscopy of single human erythrocytes at physiological ionic strength: dispersion of the aytoplasm.” Biophysical Journal, vol. 71, pp. 495-506 (1996).
Glidewell, et al., The Use of Magnetic Resonance Imaging Data and the Inclusion of Anisotropic Regions in Electrical Impedance Tomography, Biomed, Sci. Instrum. 1993; 29: 251-7.
Golberg, A. And Rubinsky, B., “A statistical model for multidimensional irreversible electroporation cell death in tissue.” Biomed Eng Online, 9, 13 pages, 2010.
Gothelf, et al., Electrochemotherapy: Results of Cancer Treatment Using Enhanced Delivery of Bleomycin by Electroporation, Cancer Treatment Reviews 2003: 29: 371-387.
Gowrishankar T.R., et al., “Microdosimetry for conventional and supra-electroporation in cells with organelles”. Biochem Biophys Res Commun, 341(4): p. 1266-76 (2006).
Griffiths, et al., a Dual-Frequency Electrical Impedance Tomography System, Phys. Met Biol., 1989, vol. 34, No. 10, pp. 1465-1476.
Griffiths, The Importance of Phase Measurement in Electrical Impedance Tomography, Phys. Med. Biol., 1987, vol. 32, No. 11, pp. 1435-1444.
Griffiths, Tissue Spectroscopy with Electrical Impedance Tomography: Computer Simulations, IEEE Transactions pn Biomedical Engineering, vol. 42, No. 9, Sep. 1995.
Gumerov, et al., the Dipole Approximation Method and Its Coupling with the Regular Boundary Element Method for Efficient Electrical Impedance Tomography, Boundary Element Technology XIII, 1999.
Hapala, Breaking the Barrier: Methods for Reversible Permeabilization of Cellular Membranes, Critical Reviews in Biotechnology, 17(2): 105-122, 1997.
Helczynska et al., “Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ.” Cancer Research, vol. 63, pp. 1441-1444 (2003).
Heller, et al., Clinical Applications of Electrochemotherapy, Advanced Drug Delivery Reviews, vol. 35, pp. 119-129, 1999.
Hjouj, M., et al., “Electroporation-Induced Bbb Disruption and Tissue Damage Depicted by MRI”, Neuro-Oncology 13: Issue suppl 3, abstract ET-32 (2011).
Hjouj, M., et al., “MRI Study on Reversible and Irreversible Electroporation Induced Blood Brain Barrier Disruption”, PLOS One, Aug. 2012, 7:8, e42817.
Co-Pending Application No. PCT/US15/30429, filed May 12, 2015.
Co-pending Application No. PCT/US19/51731, filed Sep. 18, 2019.
Co-pending application No. PCT/US19/51731 Invitation to Pay Additional Search Fees dated Oct. 14, 2010.
Co-Pending Application No. PCT/US2015/030429, Published on Nov. 19, 2015 as WO 2015/175570.
Co-Pending Application No. PCT/US2015/030429, Published Nov. 19, 2015 as WO 2015/175570.
Co-Pending U.S. Appl. No. 12/491,151, filed Jun. 24, 2009.
Co-Pending U.S. Appl. No. 13/332,133, filed Dec. 20, 2011.
Co-Pending U.S. Appl. No. 13/550,307, Aug. 13, 2018 Applicant-Initiated Interview Summary, 3 pages.
Co-Pending U.S. Appl. No. 13/550,307, Final Office Action dated Dec. 5, 2018, 17 pages.
Co-Pending U.S. Appl. No. 13/550,307, Office Actions and Responses through Mar. 2018, 133 pages.
Co-Pending U.S. Appl. No. 13/550,307, Response to Mar. 14, 2018 Non-Final Office Action dated Jul. 16, 2018, 12 pages.
Co-Pending U.S. Appl. No. 13/550,307, filed Jul. 16, 2012.
Co-Pending U.S. Appl. No. 13/919,640, filed Jun. 17, 2013.
Co-Pending U.S. Appl. No. 13/958,152, filed Aug. 2, 2013.
Co-Pending U.S. Appl. No. 13/989,175, filed May 3, 2013.
Co-Pending U.S. Appl. No. 14/012,832, Ex Parte Quayle Office Action dated Aug. 28, 2015, 6 pages.
Co-Pending U.S. Appl. No. 14/012,832, Notice of Allowance dated Nov. 4, 2015, 5 pages.
Co-Pending U.S. Appl. No. 14/012,832 , Ex Parte Quayle Office Action dated Aug. 28, 2013, 6 pages.
Co-Pending U.S. Appl. No. 14/017,210, filed Sep. 3, 2013.
Co-Pending U.S. Appl. No. 14/627,046, filed Feb. 20, 2015.
Co-Pending U.S. Appl. No. 14/686,380, Final Office Action dated May 9, 2018, 14 pages.
Co-Pending U.S. Appl. No. US 14/686,380, Final Office Action dated Sep. 3, 2019, 28 pages.
Co-Pending U.S. Appl. No. 14/686,380, Non-Final Office Action dated May 1, 2019, 18 pages.
Co-Pending U.S. Appl. No. 14/686,380, Non-Final Office Action dated Nov. 22, 2017, 11 pages.
Co-Pending U.S. Appl. No. 14/686,380, Response to Jul. 19, 2017 Restriction Requirement, dated Sep. 15, 2017, 2 pages.
Co-Pending U.S. Appl. Co. 14/686,380, Response to May 9, 2018 Final Office Action with RCE, dated Aug. 30, 2018, 14 pages.
Co-Pending U.S. Appl. No. 14/686,380, Response to Non-Final Office Action Filed Aug. 1, 2019, 11 pages.
Co-Pending U.S. Appl. No. 14/686,380, Response to Nov. 22, 2017 Non-Final Office Action dated Mar. 28, 2018, 11 pages.
Co-Pending U.S. Appl. No. 14/686,380, Restriction Requirement Jul. 19, 2017, 7 pages.
Co-Pending U.S. Appl. No. 14/686,380 filed Apr. 14, 2015.
Co-Pending U.S. Appl. No. 14/940,863, filed on Nov. 13, 2015 and Published as US 2016/0066977 dated Mar. 10, 2016.
Co-pending U.S. Appl. No. 16/152,743, filed Oct. 5, 2018.
Corovic, S., et a., “Analytical and numerical quantification and comparison of the local electric field in the tissue for different electrode configurations,” Biomed Eng Online, 6, 2007.
Cowley, Good News for Boomers, Newsweek, Dec. 30, 1996/Jan. 6, 1997.
Cox, et al., Surgical Treatment of Atrial Fibrillation: A Review, Europace (2004) 5, S20-S-29.
Crowley, Electrical Breakdown of Biomolecular Lipid Membranes as an Electromechanical Instability, Biophysical Journal, vol. 13, pp. 711-724, 1973.
Dahl et al., “Nuclear shape, mechanics, and mechanotransduction.” Circulation Research vol. 102, pp. 1307-1318 :2008).
Daud, Al., et al., “Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma,” Journal of Clinical Oncology, 26, 5896-5903, Dec 20, 2008.
Davalos, et al., Theoretical Analysis of the Thermal Effects During in Vivo Tissue Electroporation, Bioelectrochemistry, vol. 61, pp. 99-107, 2003.
Davalos, et al., a Feasibility Study for Electrical Impedance Tomography as a Means to Monitor T issue Electroporation for Molecular Medicine, IEEE Transactions on Biomedical Engineering, vol. 49, No. 4, Apr. 2002.
Davalos, et al., Tissue Ablation with Irreversible Electroporation, Annals of Biomedical Engineering, vol. 33, No. 2, pg. 223-231, Feb. 2005.
Davalos, R. V. & Rubinsky, B. Temperature considerations during irreversible electroporation. International Journal of Heat and Mass Transfer 51, 5617-5622, doi:10.1016/j.ijheatmasstransfer.2008.04.046 (2008).
Davalos, R.V. et al., “Electrical impedance tomography for imaging tissue electroporation,” IEEE Transactions on Biomedical Engineering, 51, 761-767, 2004.
Davalos, Real-Time Imaging for Molecular Medicine through Electrical Impedance Tomography of Electroporation, Dissertation for Ph.D. In Engineering-Mechanical Engineering, Graduate Division of University of California, Berkeley, 2002.
De Vuyst, E, et al., “In situ bipolar Electroporation for localized cell loading with reporter dyes and investigating gap unctional coupling”, Biophysical Journal, 94(2): p. 469-479 (2008).
Dean, Nonviral Gene Transfer to Skeletal, Smooth, and Cardiac Muscle in Living Animals, Am J. Physiol Cell Physiol 289: 233-245, 2005.
Demirbas, M. F., “Thermal Energy Storage and Phase Change Materials: An Overview” Energy Sources Part B 1(1), 5-95 (2006).
Dev, et al., Medical Applications of Electroporation, IEEE Transactions of Plasma Science, vol. 28, No. 1, pp. 206-223, Feb. 2000.
Reber{hacek over (s)}ek, M. And D. Miklav{hacek over (c)}i{hacek over (c)}, “Advantages and Disadvantages of Different Concepts of Electroporation Pulse Generation,” Automatika 52(2011) 1, 12-19.
Rols, M.P., et al., Highly Efficient Transfection of Mammalian Cells by Electric Field Pulses: Application to Large Volumes Of Cell Culture by Using a Flow System, Eur. J. Biochem. 1992, 206, pp. 115-121.
Ron et al., “Cell-based screening for membranal and cytoplasmatic markers using dielectric spectroscopy.” Biophysical ahemistry, 135 (2008) pp. 59-68.
Rossmeisl et al., “Pathology of non-thermal irreversible electroporation (N-Tire)-induced ablation of the canine brain.” Journal of Veterinary Science vol. 14, pp. 433-440 (2013).
Rossmeisl, “New Treatment Modalities for Brain Tumors in Dogs and Cats.” Veterinary Clinics of North America: Small Animal Practice 44, pp. 1013-1038 (2014).
Rubinsky et al., “Optimal Parameters for the Destruction of Prostate Cancer Using Irreversible Electroporation.” the Journal of Urology, 180 (2008) pp. 2668-2674.
Rubinsky, B., “Irreversible Electroporation in Medicine”, Technology in Cancer Research and Treatment, vol. 6, No. 4, Aug. 1, 2007, pp. 255-259.
Rubinsky, B., ed, Cryosurgery. Annu Rev. Biomed. Eng. vol. 2 2000. 157-187.
Rubinsky, B., et al., “Irreversible Electroporation: A New Ablation Modality —Clinical Implications” Technol. Cancer Res. Treatment 6(1), 37-48 (2007).
Sabuncu et al., “Dielectrophoretic separation of mouse melanoma clones.” Biomicrofluidics, vol. 4, 7 pages (2010).
Salford, L.G., et al. “A new brain tumour therapy combining bleomycin with in vivo electropermeabilization”, Biochem. . Biophys. Res. Commun., 194(2): 938-943 (1993).
Salmanzadeh et al., “Investigating dielectric properties of different stages of syngeneic murine ovarian cancer cells” Biomicrofiuidics 7, 011809 (2013), 12 pages.
Salmanzadeh et al., “Dielectrophoretic differentiation of mouse ovarian surface epithelial cells, macrophages, and Fibroblasts using contactless dielectrophoresis.” Biomicrofluidics, vol. 6, 13 Pages. (2012).
Salmanzadeh et al., “Sphingolipid Metabolites Modulate Dielectric Characteristics of Cells in a Mouse Ovarian Cancer Progression Model.” Integr. Biol., 5(6), pp. 843-852 (2013).
Sano et al., “Contactless Dielectrophoretic Spectroscopy: Examination of the Dielectric Properties of Cells Found in Blood.” Electrophoresis, 32, pp. 3164-3171, 2011.
Sano et al., “In-vitro bipolar nano- and microsecond electro-pulse bursts for irreversible electroporation therapies.” Bioelectrochemistry vol. 100, pp. 69-79 (2014).
Sano et al., “Modeling and Development of a Low Frequency Contactless Bioelectrophoresis (cDEP) Plafform to Sort cancer Cells from Dilute Whole Blood Samples_” Biosensors & Bioelectronics, 8 pages. (2011).
Sano, M. B., et al., “Towards the creation of decellularized organ constructs using irreversible electroporation and active mechanical perfusion”, Biomedical Engineering Online, Biomed Central Ltd, London, GB, vol. 9, No. 1, 10 Dec. 2010, page 83.
Saur et al., “CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer.” Gastroenterology, vol. 129, pp. 1237-1250 (2005).
Schmukler, Impedance Spectroscopy of Biological Cells, Engineering in Medicine and Biology Society, Engineering Advances: New Opportunities for Biomedical Engineers, Proceedings of the 16th Annual Internal Conference of the IEEE, vol. 1, p. A74, downloaded from IEEE Xplore website, 1994.
Schoenbach et al., “Intracellular effect of ultrashort electrical pulses.” Bioelectromagnetics, 22 (2001) pp. 440-448.
Seibert et al., “Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice.” Cancer Research, vol. 13, pp. 2223-2239 (1983).
Seidler et al., “A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors.” Proceedings of the National Academy of Sciences, vol. 105, pp. 10137-10142 '2008).
Sel, D. et al. Sequential finite element model of tissue electropermeabilization. IEEE Transactions on Biomedical Engineering 52, 816-827, doi:10.1109/tbme.2005.845212 (2005).
Sel, D., Lebar, A. M. & Miklavcic, D. Feasibility of employing model-based optimization of pulse amplitude and electrode distance for effective tumor electropermeabilization. IEEE Trans Biomed Eng 54, 773-781 (2007).
Sersa, et al., Reduced Blood Flow and Oxygenation in SA-1 Tumours after Electrochemotherapy with Cisplatin, British Journal of Cancer, 87, 1047-1054, 2002.
Sersa, et al., Tumour Blood Flow Modifying Effects of Electrochemotherapy: a Potential Vascular Targeted Mechanism, Radio!. Oncol., 37(1): 43-8, 2003.
Sharma, A. , et al., “Review on Thermal Energy Storage with Phase Change Materials and Applications”, Renewable Sustainable Energy Rev. 13(2), 318-345 (2009).
Sharma, et al., Poloxamer 188 Decreases Susceptibility of Artificial Lipid Membranes to Electroporation, Biophysical Journal, vol. 71, No. 6, pp. 3229-3241, Dec. 1996.
Shiina, S., et al, Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR, 1993, 160: p. 1023-8.
Szot et al., “3D in vitro bioengineered tumors based on collagen I hydrogels.” Biomaterials vol. 32, pp. 7905-7912 (2011).
Talele, S., et al., “Modelling single cell electroporation with bipolar pulse parameters and dynamic pore radii”. Journal of Electrostatics, 68(3): p. 261-274 (2010).
Tekle, Ephrem, R. Dean Astumian, and R Boon Chock, Electroporation by using bipolar oscillating electric field: An Improved method for DNA transfection of NIH 3T3 cells, Proc. Natl. Acad. Sci., vol. 88, pp. 4230-4234, May 1991, Biochemistry.
Thompson, et al., To determine whether the temperature of 2% lignocaine gel affects the initial discomfort which may be associated with its instillation into the male urethra, BJU International (1999), 84, 1035-1037.
Thomson, K. R., et al., “Investigation of the Safety of Irreversible Electroporation in Humans” J. Vascular Int. Radio. 22 (5), 611-621 (2011).
TUNA—Suggested Local Anesthesia Guidelines, no. date available.
Verbridge et al., “Oxygen-Controlled Three-Dimensional Cultures to Analyze Tumor Angiogenesis.” Tissue Engineering, Part A vol. 16, pp. 2133-2141 (2010).
Vernier, P.T., et al., “Nanoelectropulse-driven membrane perturbation and small molecule permeabilization”, Bmc Cell Biology, 7 (2006).
Vidamed, Inc., Transurethral Needle Ablation (Tuna): Highlights from Worldwide Clinical Studies, Vidamed's Office TUNA System, 2001.
Wasson, Elisa M. et al. The Feasibility of Enhancing Susceptibility of Glioblastoma Cells to IRE Using a Calcium Adjuvant. Annals of Biomedical Engineering, vol. 45, No. 11, Nov. 2017 pp. 2535-2547.
Weaver et al., “A brief overview of electroporation pulse strength-duration space: A region where additional Intracellular effects are expected.” Bioelectrochemistry vol. 87, pp. 236-243 (2012).
Weaver, Electroporation: A General Phenomenon for Manipulating Cells and Tissues, Journal of Cellular Biochemistry, 51: 426-435, 1993.
Weaver, et al., Theory of Electroporation: A Review, Bioelectrochemistry and Bioenergetics, vol. 41, pp. 136-160, 1996.
Weaver, J. C., Electroporation of biological membranes from multicellular to nano scales, IEEE Tms. Dielectr. Electr. Insul 10, 754-768 (2003).
Weaver, J.C., “Electroporation of cells and tissues”, IEEE Transactions on Plasma Science, 28(1): p. 24-33 (2000).
Weisstein: Cassini Ovals. From MathWorld—A. Wolfram Web Resource; Apr. 30, 2010; http://mathworld.wolfram.com/ (updated May 18, 2011).
Wimmer, Thomas, et al., “Planning Irreversible Electroporation (IRE) in the Porcine Kidney: Are Numerical Simulations Reliable for Predicting Empiric Ablation Outcomes?”, Cardiovasc Intervent Radio. Feb. 2015; 38(1): 182-190. doi:10.1007/s00270-014-0905-2.
Yang et al., “Dielectric properties of human leukocyte subpopulations determined by electrorotation as a cell separation criterion.” Biophysical Journal, vol. 76, pp. 3307-3314 (1999).
Yao et al., “Study of transmembrane potentials of inner and outer membranes induced by pulsed-electric-field model and simulation.” IEEE Trans Plasma Sci, 2007. 35(5): p. 1541-1549.
Zhang, Y., et al., MR imaging to assess immediate response to irreversible electroporation for targeted ablation of liver tissues: preclinical feasibility studies in a rodent model. Radiology, 2010.256(2): p. 424-32.
Co-pending application No. PCT/US19/51731 International Search Report and Written Opinion dated Feb. 20, 2020, 19 pgs.

Related Publications (1)

	Number	Date	Country
	20170360326 A1	Dec 2017	US

Provisional Applications (1)

	Number	Date	Country
	62091703	Dec 2014	US

Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract